Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3908
Name lung non-small cell carcinoma
Definition A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA act mut Pictilisib lung non-small cell carcinoma sensitive detail...
PTEN del PF-04691502 lung non-small cell carcinoma predicted - sensitive detail...
PTEN loss Pictilisib lung non-small cell carcinoma sensitive detail...
BRAF Y472C Dasatinib lung non-small cell carcinoma sensitive detail...
BRAF G466V Dasatinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Vemurafenib lung non-small cell carcinoma sensitive detail...
BRAF V600E Dabrafenib lung non-small cell carcinoma sensitive detail...
TP53 P72R Cisplatin + Irinotecan lung non-small cell carcinoma sensitive detail...
ALK fusion ALK S1206Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
PIK3CA E545K Copanlisib + Paclitaxel lung non-small cell carcinoma sensitive detail...
RET act mut Ponatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Belizatinib lung non-small cell carcinoma no benefit detail...
ALK positive Ensartinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK G1269A Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ensartinib + Sirolimus lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R Ceritinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK V1180L Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Lorlatinib lung non-small cell carcinoma sensitive detail...
PIK3CA mutant PWT33597 lung non-small cell carcinoma sensitive detail...
ALK rearrange Crizotinib lung non-small cell carcinoma sensitive detail...
CDKN2A loss Palbociclib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion Alectinib lung non-small cell carcinoma sensitive detail...
ALK fusion Brigatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Brigatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Ceritinib lung non-small cell carcinoma conflicting detail...
NRAS Q61K Gedatolisib lung non-small cell carcinoma decreased response detail...
TP53 R158G Gedatolisib lung non-small cell carcinoma sensitive detail...
STK11 mutant Gedatolisib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171T Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Ceritinib + Crizotinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK mut Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK V1180L Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK V1180L Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange Ceritinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Brigatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Alectinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Ensartinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK TAE226 lung non-small cell carcinoma sensitive detail...
BRAF G469A TAE226 lung non-small cell carcinoma sensitive detail...
BRAF G466V TAE226 lung non-small cell carcinoma sensitive detail...
FGFR1 amp Debio 1347 lung non-small cell carcinoma sensitive detail...
TP53 R248W APR-246 + Cisplatin lung non-small cell carcinoma sensitive detail...
TP53 R273H APR-246 + Cisplatin lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Alectinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Navitoclax + Vemurafenib lung non-small cell carcinoma sensitive detail...
BRAF V600E Navitoclax + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Trametinib + TW-37 lung non-small cell carcinoma sensitive detail...
BRAF V600E TW-37 + Vemurafenib lung non-small cell carcinoma sensitive detail...
TP53 wild-type CEP-8983 + Cisplatin lung non-small cell carcinoma sensitive detail...
TP53 mutant CEP-8983 + Cisplatin lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY LY3009120 lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Trametinib lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Dabrafenib lung non-small cell carcinoma resistant detail...
ROS1 rearrange Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171S Alectinib lung non-small cell carcinoma predicted - resistant detail...
ATM loss Ceralasertib + Cisplatin lung non-small cell carcinoma sensitive detail...
EML4 - ALK Entrectinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK C1156Y Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Luminespib lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK C1156Y ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK C1156Y ALK L1198F Crizotinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib lung non-small cell carcinoma sensitive detail...
ALK fusion Lorlatinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK fusion ALK G1202R Lorlatinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp AZD4547 lung non-small cell carcinoma sensitive detail...
RET fusion Vandetanib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange ALK neg Crizotinib lung non-small cell carcinoma sensitive detail...
ALK mutant Crizotinib + Onalespib lung non-small cell carcinoma no benefit detail...
CD274 positive Pembrolizumab lung non-small cell carcinoma sensitive detail...
BRAF L485Y GDC0879 lung non-small cell carcinoma resistant detail...
BRAF wild-type GDC0879 lung non-small cell carcinoma resistant detail...
BRAF L597V NRAS Q61K AZ628 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K TAK-632 lung non-small cell carcinoma sensitive detail...
BRAF G466V TAK-632 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K PLX7904 lung non-small cell carcinoma decreased response detail...
BRAF L597V NRAS Q61K Vemurafenib lung non-small cell carcinoma decreased response detail...
BRAF G466V Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF L597V NRAS Q61K Dabrafenib lung non-small cell carcinoma decreased response detail...
TP53 wild-type KRT-232 lung non-small cell carcinoma sensitive detail...
TP53 wild-type Cisplatin + KRT-232 lung non-small cell carcinoma sensitive detail...
TP53 wild-type Carboplatin + KRT-232 lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Everolimus + Pimasertib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib + Sorafenib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib + Regorafenib lung non-small cell carcinoma sensitive detail...
PIK3CA mutant PF-04691502 lung non-small cell carcinoma sensitive detail...
FGFR1 amp PRN1371 lung non-small cell carcinoma sensitive detail...
FGFR2 amp PRN1371 lung non-small cell carcinoma sensitive detail...
FGFR3 amp PRN1371 lung non-small cell carcinoma sensitive detail...
ALK rearrange Nivolumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Pembrolizumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Durvalumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Atezolizumab lung non-small cell carcinoma no benefit detail...
FGFR1 amp RO4987655 lung non-small cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung non-small cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung non-small cell carcinoma no benefit detail...
ALK rearrange ALK E1210K Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange MAP2K1 K57N Ceritinib + Selumetinib lung non-small cell carcinoma sensitive detail...
PIK3CA G118D LY3023414 lung non-small cell carcinoma sensitive detail...
EML4 - ALK Afatinib + Alectinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp E7090 lung non-small cell carcinoma sensitive detail...
FGFR1 amp NGI-1 lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK Brigatinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF mutant Dabrafenib + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469V Sorafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469A Vemurafenib lung non-small cell carcinoma resistant detail...
BRAF G469A Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Trametinib + Vemurafenib lung non-small cell carcinoma conflicting detail...
ROS1 rearrange NPS-1034 lung non-small cell carcinoma sensitive detail...
STK11 inact mut Trametinib lung non-small cell carcinoma sensitive detail...
STK11 Q37* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 E199* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 W332* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 dec exp Trametinib lung non-small cell carcinoma sensitive detail...
STK11 K48fs Trametinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Taletrectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK positive Entrectinib lung non-small cell carcinoma sensitive detail...
RET rearrange Alectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK I1171N Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK G1202R Alectinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 rearrange Entrectinib lung non-small cell carcinoma sensitive detail...
STK11 E57fs Trametinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK F1245C Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK F1245C Ceritinib lung non-small cell carcinoma sensitive detail...
RET rearrange Cabozantinib lung non-small cell carcinoma sensitive detail...
RET rearrange Vandetanib lung non-small cell carcinoma sensitive detail...
RET rearrange Sunitinib lung non-small cell carcinoma predicted - sensitive detail...
RET rearrange RXDX-105 lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
TP53 mutant Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange Ceritinib lung non-small cell carcinoma sensitive detail...
PIK3CA H1047X Taselisib lung non-small cell carcinoma sensitive detail...
FGFR1 amp GSK3052230 lung non-small cell carcinoma sensitive detail...
BRAF G466V Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G466V NRAS Q61K Trametinib lung non-small cell carcinoma sensitive detail...
BRAF mutant KO-947 lung non-small cell carcinoma predicted - sensitive detail...
BRAF G466V Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
TP53 negative Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 R175H Seliciclib lung non-small cell carcinoma resistant detail...
TP53 S215G Seliciclib lung non-small cell carcinoma resistant detail...
TP53 Y220C Seliciclib lung non-small cell carcinoma resistant detail...
TP53 P98A Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 A159V Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 Y234C Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 wild-type Seliciclib lung non-small cell carcinoma sensitive detail...
NRAS mutant KO-947 lung non-small cell carcinoma predicted - sensitive detail...
STK11 mutant unspecified PD-1 antibody lung non-small cell carcinoma decreased response detail...
BRAF mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - sensitive detail...
FGFR1 amp NRAS amp Infigratinib lung non-small cell carcinoma resistant detail...
FGFR1 amp NRAS amp Trametinib lung non-small cell carcinoma resistant detail...
FGFR1 amp NRAS amp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp NRAS over exp Infigratinib lung non-small cell carcinoma decreased response detail...
FGFR1 amp NRAS over exp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Infigratinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Crizotinib + Filgotinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK F1174V Alectinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171S ALK F1174V Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange Lorlatinib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171T Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK F1174V Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1152R Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1196M ALK G1269A Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK T1151dup ALK G1269A Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK amp Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK G1202R Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK CEP-28122 lung non-small cell carcinoma sensitive detail...
ALK negative CEP-28122 lung non-small cell carcinoma resistant detail...
ALK rearrange ALK L1196M Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK S1206Y Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK C1156Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 rearrange Alectinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Erlotinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Gefitinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Afatinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Osimertinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Erlotinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Gefitinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Afatinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Osimertinib lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK F1174V ALK G1202R Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK F1174C Ceritinib lung non-small cell carcinoma resistant detail...
CD274 pos STK11 mut unspecified PD-1 antibody lung non-small cell carcinoma predicted - resistant detail...
BRAF act mut RAF709 lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK I1171N ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK I1171N ALK D1203N Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK C1156Y ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK L1196M ALK G1202R Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK G1202R ALK L1204V ALK G1269A Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK D1203N ALK E1210K ALK G1269A Lorlatinib lung non-small cell carcinoma resistant detail...
RET fusion Selpercatinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion ROS1 L1951R ROS1 L2026M Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion ROS1 L1951R ROS1 L2026M Ceritinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK E1210K Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK S1206C ALK E1210K Brigatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK F1174L ALK L1198V Brigatinib lung non-small cell carcinoma resistant detail...
ROS1 fusion KIT D816G Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK FGFR1 amp Brigatinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK HRAS amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
BRAF G469A Encorafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Dabrafenib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK G1202R Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171N Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK I1171T Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK V1180L Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK V1180L Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171T Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK V1180L ALK L1196M ALK G1202R Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK D1203N Brigatinib lung non-small cell carcinoma predicted - resistant detail...
KEAP1 mutant Radiotherapy lung non-small cell carcinoma predicted - resistant detail...
BRAF D594N RMC-4550 lung non-small cell carcinoma predicted - sensitive detail...
BRAF N581D RMC-4550 lung non-small cell carcinoma predicted - sensitive detail...
RET rearrange Ponatinib lung non-small cell carcinoma no benefit detail...
FGFR1 V561M AZD4547 lung non-small cell carcinoma resistant detail...
ALK rearrange TP53 mut Crizotinib lung non-small cell carcinoma decreased response detail...
ALK rearrange TP53 mut Ceritinib lung non-small cell carcinoma decreased response detail...
ALK rearrange TP53 mut Alectinib lung non-small cell carcinoma decreased response detail...
ALK rearrange TP53 mut Brigatinib lung non-small cell carcinoma decreased response detail...
STK11 mutant unspecified PD-L1 antibody lung non-small cell carcinoma decreased response detail...
BRAF mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK G1202R ALK G1269A Lorlatinib lung non-small cell carcinoma resistant detail...
CDKN2A negative Palbociclib lung non-small cell carcinoma predicted - sensitive detail...
CDKN2A negative Everolimus + Palbociclib lung non-small cell carcinoma sensitive detail...
CDKN2A negative Palbociclib + Sirolimus lung non-small cell carcinoma sensitive detail...
CDKN2A negative Palbociclib + PF-04691502 lung non-small cell carcinoma sensitive detail...
ALK fusion ALK G1202R KIT amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK Iruplinalkib lung non-small cell carcinoma sensitive detail...
BRAF V600X Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600E/K Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600K Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Brigatinib lung non-small cell carcinoma no benefit detail...
CDKN2A mutant Palbociclib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion Crizotinib lung non-small cell carcinoma sensitive detail...
ALK fusion Ceritinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK MTI-31 lung non-small cell carcinoma sensitive detail...
ROS1 rearrange TP53 mut Crizotinib lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange PIK3CA E545K Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 rearrange ROS1 L2026M TP53 P278H Crizotinib lung non-small cell carcinoma predicted - resistant detail...
CD274 over exp Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Atezolizumab lung non-small cell carcinoma sensitive detail...
CD274 over exp Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Ipilimumab lung non-small cell carcinoma predicted - sensitive detail...
TP53 mutant Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
TP53 mutant Ipilimumab + Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK G1202R Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK G1202R Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK G1202R Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK D1203N Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174C Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174L Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
ROS1 positive Entrectinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Entrectinib lung non-small cell carcinoma sensitive detail...
CD274 positive SL-279252 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK E1303K Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion Ensartinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ensartinib lung non-small cell carcinoma sensitive detail...
ALK rearrange PLB1003 lung non-small cell carcinoma predicted - sensitive detail...
ATM del AZD7648 + Olaparib lung non-small cell carcinoma sensitive detail...
ATM del AZD7648 lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK F1174C ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174L ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK T1151M ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
CD274 positive Nivolumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Crizotinib + Onalespib lung non-small cell carcinoma no benefit detail...
ALK C1156Y ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK F1174V ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK F1174L ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1196M ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK G1202R ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171T ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171S ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152R ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK amp ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152V ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
FGFR1 amp Zotatifin lung non-small cell carcinoma sensitive detail...
ATM del Olaparib lung non-small cell carcinoma sensitive detail...
CD274 positive Atezolizumab + Carboplatin + Nab-paclitaxel lung non-small cell carcinoma sensitive detail...
BRAF V600X Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600D Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600M Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600K Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF N581S Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF K601E Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF K601N Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G466A Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G469V Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G596R Vemurafenib lung non-small cell carcinoma no benefit detail...
TP53 R175H SLMP53-2 lung non-small cell carcinoma sensitive detail...
TP53 Y220C SLMP53-2 lung non-small cell carcinoma sensitive detail...
TP53 G245S SLMP53-2 lung non-small cell carcinoma sensitive detail...
PIK3CA mutant Sulindac lung non-small cell carcinoma predicted - sensitive detail...
PIK3CA act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
PTEN inact mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
NRAS act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
BRAF act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 S37F Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 S37C Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 D32V Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 G34V Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 T41I Osimertinib lung non-small cell carcinoma predicted - resistant detail...
TP53 mutant Osimertinib lung non-small cell carcinoma not predictive detail...
TP53 inact mut Osimertinib lung non-small cell carcinoma not predictive detail...
ARID1A mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - sensitive detail...
ARID1A mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - sensitive detail...
PIK3CA amp Sulindac lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Atezolizumab + Tiragolumab lung non-small cell carcinoma predicted - sensitive detail...
RET fusion Pralsetinib lung non-small cell carcinoma sensitive detail...
RET rearrange Selpercatinib lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Cisplatin + Pembrolizumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Pembrolizumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Taletrectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK mutant Belizatinib lung non-small cell carcinoma no benefit detail...
ALK amp Belizatinib lung non-small cell carcinoma no benefit detail...
STK11 loss Vistusertib lung non-small cell carcinoma no benefit detail...
FGFR2 V514L AZD4547 lung non-small cell carcinoma no benefit detail...
FGFR3 P573S AZD4547 lung non-small cell carcinoma no benefit detail...
FGFR3 S756P AZD4547 lung non-small cell carcinoma no benefit detail...
CD274 positive Nivolumab + Pegilodecakin lung non-small cell carcinoma predicted - sensitive detail...
CD274 amp Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
RET rearrange Pralsetinib lung non-small cell carcinoma sensitive detail...
ARID1A inact mut unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
PIK3CA E545K T-2143 lung non-small cell carcinoma sensitive detail...
BRAF G596V Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
NRAS Q61K BI-3406 lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK L1196Q Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK L1196Q Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Pembrolizumab lung non-small cell carcinoma not predictive detail...
BRAF V600E Nivolumab lung non-small cell carcinoma not predictive detail...
BRAF mut CD274 pos Pembrolizumab lung non-small cell carcinoma not predictive detail...
BRAF mut CD274 pos Nivolumab lung non-small cell carcinoma not predictive detail...
BRAF mut CD274 pos Atezolizumab lung non-small cell carcinoma not predictive detail...
BRAF V600E Atezolizumab lung non-small cell carcinoma not predictive detail...
BRAF mutant unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
BRAF amp unspecified immune checkpoint inhibitor lung non-small cell carcinoma not predictive detail...
BRAF V600E unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
RET fusion unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
ROS1 fusion unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
RET mutant unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
ALK positive Lorlatinib lung non-small cell carcinoma sensitive detail...
KEAP1 dec exp Radiotherapy + Telaglenastat lung non-small cell carcinoma sensitive detail...
BRAF V600E FGFR2 A553D Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E PIK3CA E545K Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Cemiplimab lung non-small cell carcinoma sensitive detail...
ALK rearrange Ipilimumab + Nivolumab lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK I1171N Gilteritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171N Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK I1171N Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171N Entrectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Gilteritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK TP53 Q331* Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 Q331* Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 V274fs Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 V274fs Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 Q331* Alectinib + Ixazomib lung non-small cell carcinoma sensitive detail...
EML4 - ALK TP53 V274fs Alectinib + Ixazomib lung non-small cell carcinoma sensitive detail...
CD274 dec exp Avelumab + Pepinemab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Durvalumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Retifanlimab lung non-small cell carcinoma predicted - sensitive detail...
TP53 Q331* AZ32 + Radiotherapy lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib + SHP099 lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib + Selumetinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib + RMC-4550 lung non-small cell carcinoma sensitive detail...
ALK fusion ALK T1151dup Ceritinib lung non-small cell carcinoma no benefit detail...
ALK fusion ALK T1151dup Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Ipilimumab + Nivolumab lung non-small cell carcinoma sensitive detail...
KEAP1 D236H Gefitinib lung non-small cell carcinoma resistant detail...
KEAP1 D236H Afatinib lung non-small cell carcinoma resistant detail...
KEAP1 D236H Osimertinib lung non-small cell carcinoma resistant detail...
CDKN2A inact mut unspecified immune checkpoint inhibitor lung non-small cell carcinoma not predictive detail...
CDKN2A del unspecified immune checkpoint inhibitor lung non-small cell carcinoma not predictive detail...
CD274 positive Anlotinib + Cadonilimab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Atezolizumab lung non-small cell carcinoma sensitive detail...
CD274 positive Durvalumab + Vactosertib lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion ROS1 S1986F ROS1 L2000V Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
CD274 over exp Niraparib + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Niraparib + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange Repotrectinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK G1202del Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK F1174X Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK XMU-MP-5 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y ALK L1196M ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ROS1 rearrange Crizotinib lung non-small cell carcinoma predicted - sensitive detail...
NRAS Q61K Lifirafenib + PD-0325901 lung non-small cell carcinoma sensitive detail...
NRAS Q61K Lifirafenib + Pimasertib lung non-small cell carcinoma sensitive detail...
ALK rearrange Iruplinalkib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Iruplinalkib lung non-small cell carcinoma sensitive detail...
ALK rearrange Ceritinib + Ribociclib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK G1202R Ceritinib + HJC0152 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R HJC0152 lung non-small cell carcinoma sensitive detail...
FGFR1 amp CPL304110 lung non-small cell carcinoma sensitive detail...
BRAF V600E LTT462 + LXH 254 lung non-small cell carcinoma predicted - sensitive detail...
BRAF K601N LTT462 + LXH 254 lung non-small cell carcinoma predicted - sensitive detail...
BRAF G466A LTT462 + LXH 254 lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange SAF-189s lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion ALK C1156Y ALK L1198F Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK L1196M ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK G1202R ALK L1204V ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK D1203N ALK E1210K ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK G1202R ALK S1206F ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion ROS1 G2032R Taletrectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion TQ-B3139 lung non-small cell carcinoma sensitive detail...
EML4 - ALK TQ-B3139 lung non-small cell carcinoma sensitive detail...
CD274 positive MT-6402 lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK APG-2449 lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK L1196Q Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK E1129V Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK amp Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171S Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174L Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174V Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174S Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK E1129V Ceritinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171T ALK F1174V Ceritinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E BRAF K601_W604del Dabrafenib + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion APG-2449 lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion NUV-520 lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion ROS1 G2032R NUV-520 lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange Conteltinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M ALK G1202R NUV-655 lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK T1151M ALK G1202R NUV-655 lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK G1202R NUV-655 lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Cetrelimab lung non-small cell carcinoma predicted - sensitive detail...
ALK positive Brigatinib lung non-small cell carcinoma no benefit detail...
ALK V1180L Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK V1180Y Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171T ALK G1269A Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Carboplatin + Cemiplimab + Paclitaxel lung non-small cell carcinoma sensitive detail...
CD274 positive Cemiplimab + Cisplatin + Paclitaxel lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Cemiplimab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Cemiplimab + Cisplatin + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab lung non-small cell carcinoma sensitive detail...
CD274 positive Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab lung non-small cell carcinoma sensitive detail...
ATM Q1919P RP-3500 lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Carboplatin + Pembrolizumab + Pemetrexed Disodium lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange Carboplatin + Paclitaxel + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Surufatinib + Toripalimab-tpzi lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Lifirafenib + PD-0325901 lung non-small cell carcinoma predicted - sensitive detail...
RET fusion HS-10365 lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Binimetinib + Encorafenib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Lorlatinib + PF-07284892 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R Lorlatinib + PF-07284892 lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion Repotrectinib lung non-small cell carcinoma sensitive detail...
CD274 positive AZD2936 lung non-small cell carcinoma predicted - sensitive detail...
ATM Q1331H ATM I1441fs Radiotherapy lung non-small cell carcinoma predicted - sensitive detail...
BRAF G466V IHMT-RAF-128 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K IHMT-RAF-128 lung non-small cell carcinoma sensitive detail...
ROS1 rearrange TQ-B3101 lung non-small cell carcinoma sensitive detail...
ROS1 fusion TQ-B3139 lung non-small cell carcinoma predicted - sensitive detail...
CD274 pos STK11 mut Pembrolizumab lung non-small cell carcinoma not predictive detail...
CD274 pos KEAP1 mut Pembrolizumab lung non-small cell carcinoma not predictive detail...
ALK rearrange TQ-B3139 lung non-small cell carcinoma sensitive detail...
PBRM1 mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - resistant detail...
PBRM1 mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - resistant detail...
BRAF V600X Tunlametinib + Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp IO102-IO103 + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion ROS1 G2032R Repotrectinib lung non-small cell carcinoma predicted - sensitive detail...
RET amp Selpercatinib lung non-small cell carcinoma predicted - sensitive detail...
RET mutant EP0031 lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469A SIJ777 lung non-small cell carcinoma sensitive detail...
BRAF G466V SIJ777 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK T1151M Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152V ALK G1269A Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK E1210K Ensartinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK S1206F Ensartinib lung non-small cell carcinoma predicted - resistant detail...
BRAF L485_P490delinsY LXH 254 lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Encorafenib lung non-small cell carcinoma decreased response detail...
BRAF L485_P490delinsY Sorafenib lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Ulixertinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF L485_P490delinsY LXH 254 + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF L485_P490delinsY Sorafenib + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange Ficonalkib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Afatinib + Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Afatinib + Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F Afatinib + Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M ALK D1203N Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK G1202R Ficonalkib lung non-small cell carcinoma predicted - sensitive detail...
ATM inact mut Ceralasertib + Durvalumab lung non-small cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00150657 Phase II Bevacizumab + Carboplatin + Gemcitabine Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer Unknown status USA 0
NCT00254319 Phase II Carboplatin Bevacizumab + Pemetrexed Disodium Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Unknown status USA 0
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00547105 Phase II Erlotinib Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer Completed USA 0
NCT00569296 Phase I Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer Terminated USA 0
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) Completed USA | AUS 2
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00828009 Phase II Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT00932451 Phase II Crizotinib An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT00950365 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT00975767 Phase Ib/II Docetaxel + Glesatinib Erlotinib + Glesatinib A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer Terminated USA 0
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed USA 0
NCT00979212 Phase II Panitumumab Carboplatin + Paclitaxel Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) Completed USA 0
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT00997334 Phase II Erlotinib Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC Completed USA 0
NCT01005797 Phase I Panobinostat + Sorafenib Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Completed USA 0
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Completed USA 0
NCT01059552 Phase I Vorinostat Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT01061788 Phase I Everolimus + Ganitumab + Panitumumab A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer Completed USA 0
NCT01107626 Phase III Pemetrexed Disodium Bevacizumab Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01179269 Phase II Paclitaxel + Pazopanib Stage IIIB/IV Non-Small Cell Lung Cancer Withdrawn 0
NCT01210378 Phase II Nitroglycerin Nitroglycerin in Non-small Cell Lung Cancer Terminated 1
NCT01233687 Phase Ib/II Rilotumumab Erlotinib AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT01248247 Phase I Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study Completed USA 0
NCT01263782 Phase II Bevacizumab Carboplatin + Pemetrexed Disodium Cixutumumab BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer Completed USA 0
NCT01288430 Phase I DS-2248 A Study of DS-2248, in Subjects With Advanced Solid Tumors Terminated USA 0
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | CAN | AUS 0
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA | AUS 1
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA | ESP 1
NCT01336634 Phase II Dabrafenib Dabrafenib + Trametinib Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Completed USA | ITA | GBR | FRA | ESP | DEU 5
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Disodium Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed USA 0
NCT01344824 Phase II Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers Completed USA 0
NCT01351415 Phase III Bevacizumab A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 11
NCT01383148 Phase Ib/II MVA-MUC1-IL2 vaccine Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated USA | ITA | GBR | FRA | ESP | DEU | BEL 3
NCT01386385 Phase Ib/II Carboplatin + Paclitaxel Carboplatin + Etoposide + Veliparib Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed USA 0
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed USA | ITA | FRA | ESP 0
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Completed 0
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Completed USA | CAN 0
NCT01455389 Phase Ib/II Quaratusugene Ozeplasmid Erlotinib Diphenhydramine Dexamethasone FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer Terminated USA 0
NCT01456325 Phase III Erlotinib Onartuzumab A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 18
NCT01465802 Phase II Dacomitinib Alclometasone Doxycycline Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed USA 1
NCT01487265 Phase II Buparlisib + Erlotinib Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib Completed USA 0
NCT01493843 Phase II Carboplatin Pictilisib Bevacizumab Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT01514864 Phase II Dasatinib Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Terminated USA | GBR | DEU | CAN 3
NCT01526928 Phase Ib/II Rociletinib Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients Terminated USA | FRA | AUS 1
NCT01532089 Phase II Bevacizumab Bevacizumab + Erlotinib Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Completed USA 0
NCT01537744 Phase I Azacitidine + Romidepsin A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer Completed USA 0
NCT01545947 Phase I Azacitidine + Onatasertib Erlotinib + Onatasertib Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer Completed USA | ESP 0
NCT01553942 Phase II Afatinib Cisplatin Pemetrexed Disodium Afatinib With CT and RT for EGFR-Mutant NSCLC Unknown status USA 0
NCT01573702 Phase II Erlotinib Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Completed USA 0
NCT01574729 Phase II rAD-p53 Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma Unknown status 1
NCT01578551 Phase II Metformin Carboplatin + Paclitaxel Bevacizumab A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Terminated USA 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | GBR | FRA | ESP | AUS 2
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | CAN 1
NCT01620190 Phase II Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer Completed USA 0
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed USA 0
NCT01628471 Phase Ib/II Decitabine + Genistein MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer Completed CAN 0
NCT01630733 Phase III Docetaxel Custirsen + Docetaxel A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Unknown status USA | ITA | ESP | DEU | AUS 10
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity Recruiting USA 0
NCT01642251 Phase Ib/II Cisplatin + Etoposide Veliparib Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT01646125 Phase II Docetaxel Luminespib Pemetrexed Disodium An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Terminated USA | ITA | GBR | FRA | ESP 7
NCT01647711 Phase I Afatinib A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations Completed USA 0
NCT01649284 Phase I Afatinib Afatinib Expanded Access Program Approved for marketing USA 0
NCT01649947 Phase II Bevacizumab + Carboplatin + Hydroxychloroquine + Paclitaxel Carboplatin + Hydroxychloroquine + Paclitaxel Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II Completed USA 0
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed USA | CAN | BEL 0
NCT01664754 Phase I Pemetrexed Disodium Carboplatin Exemestane Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer Completed USA 0
NCT01676714 Phase II Dovitinib Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Completed USA 0
NCT01700400 Phase I Carboplatin Everolimus Bevacizumab Pemetrexed Disodium Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Completed USA 0
NCT01708993 Phase II Docetaxel Pemetrexed Disodium Pelareorep + Pemetrexed Disodium Docetaxel + Pelareorep Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Completed CAN 0
NCT01712217 Phase Ib/II Crizotinib Onalespib A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Completed USA | FRA | ESP | CAN 1
NCT01717482 Phase II Metformin Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer Terminated USA 0
NCT01720836 Phase Ib/II MUC1 peptide-Poly-ICLC vaccine Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer Recruiting USA 0
NCT01723800 Phase I Buparlisib + Carboplatin + Pemetrexed Disodium PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer Completed USA 0
NCT01725165 Phase II Oligometastatic Disease Active, not recruiting USA | CAN 0
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01746251 Phase II Afatinib Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation Unknown status USA 0
NCT01750281 Phase II Docetaxel Docetaxel + Selumetinib Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Completed USA | FRA | DEU 5
NCT01752400 Phase II Luminespib AUY922 for Advanced ALK-positive NSCLC Completed USA 0
NCT01769391 Phase II Necitumumab Carboplatin + Paclitaxel A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer Completed USA | DEU 4
NCT01772797 Phase I Ceritinib Luminespib Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Completed USA | ITA | ESP | AUS 1
NCT01783197 Phase I Selumetinib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Completed CAN 0
NCT01784640 Phase I Luminespib + Pemetrexed Disodium Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Completed USA 0
NCT01788566 Phase II Cisplatin + Gemcitabine + Necitumumab A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer Completed USA | FRA | ESP | CAN 3
NCT01798485 Phase III Ganetespib Docetaxel A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 11
NCT01801111 Phase II Erlotinib Alectinib A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 8
NCT01802632 Phase Ib/II Osimertinib AZD9291 First Time In Patients Ascending Dose Study (AURA) Completed USA | ITA | GBR | FRA | ESP | DEU | AUS 3
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01813734 Phase II Ponatinib Ponatinib in Advanced NSCLC w/ RET Translocations Completed USA 0
NCT01820754 Phase II Cisplatin Ipilimumab Carboplatin Paclitaxel Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT01822496 Phase II Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated USA 0
NCT01828112 Phase III Docetaxel Pemetrexed Disodium Ceritinib LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 12
NCT01829217 Phase II Sunitinib Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed USA 0
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed USA | ESP 1
NCT01833143 Phase II Bortezomib Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D Completed USA 0
NCT01837329 Phase I Tetrathiomolybdate Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer Completed USA 0
NCT01839955 Phase Ib/II Erlotinib + Quinacrine Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer Completed USA 0
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated USA 0
NCT01851369 Phase Ib/II Temozolomide + TRC102 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Completed USA 0
NCT01854034 Phase II Luminespib Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Completed USA 0
NCT01857271 Phase II Erlotinib Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated USA 0
NCT01858389 Phase II Dacomitinib A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer Completed USA 1
NCT01859026 Phase I Binimetinib + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Completed USA 0
NCT01866410 Phase II Cabozantinib + Erlotinib Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer Completed USA 0
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed USA | GBR | ESP | BEL 3
NCT01871805 Phase Ib/II Alectinib A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Completed USA | CAN 0
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed USA | GBR | ESP | CAN 0
NCT01887886 Phase III Erlotinib + Onartuzumab A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation Completed USA | FRA | ESP | DEU 4
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed USA 0
NCT01900652 Phase II Emibetuzumab + Erlotinib Emibetuzumab A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 3
NCT01903993 Phase II Atezolizumab A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 5
NCT01911325 Phase Ib/II Buparlisib Docetaxel Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Terminated USA | ITA | FRA | ESP | DEU | BEL 2
NCT01911507 Phase I Capmatinib + Erlotinib INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer Completed USA 0
NCT01912625 Phase I Carboplatin + Paclitaxel + Trametinib Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Terminated USA 0
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | ITA | GBR | ESP | CAN 0
NCT01928160 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Withdrawn 0
NCT01928576 Phase II Nivolumab Entinostat Azacitidine Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. Completed USA 0
NCT01933932 Phase III Docetaxel + Selumetinib Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT01935947 Phase II Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Disodium Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Terminated USA 0
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed USA 0
NCT01947608 Phase I Ceritinib Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC No longer available USA 9
NCT01951690 Phase II Defactinib Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Completed USA 0
NCT01957007 Phase I Docetaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC Completed USA 0
NCT01966003 Phase III Bevacizumab Bevacizumab-awwb Carboplatin + Paclitaxel Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer Completed USA | AUS 1
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | AUS 1
NCT01967095 Phase I Erlotinib Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Completed USA 0
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 6
NCT01970865 Phase II Lorlatinib Crizotinib A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn USA 0
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA | FRA | ESP | DEU 3
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | DEU | CAN | AUS 2
NCT01993810 Phase III Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Active, not recruiting USA 0
NCT01998126 Phase I Erlotinib + Ipilimumab Crizotinib + Ipilimumab Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts Completed USA 0
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed USA 0
NCT01999985 Phase I Afatinib + Dasatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02000947 Phase Ib/II Durvalumab + Tremelimumab A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | BEL | AUS 2
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed USA | GBR | FRA | ESP 4
NCT02008227 Phase III Docetaxel Atezolizumab A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 23
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02013219 Phase I Alectinib + Atezolizumab Atezolizumab + Erlotinib A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer Completed USA | GBR | FRA | ESP 2
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed USA 0
NCT02019979 Phase II Metformin Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO) Terminated USA 0
NCT02022982 Phase Ib/II Palbociclib + PD-0325901 PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Active, not recruiting USA 0
NCT02031458 Phase II Atezolizumab A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn USA 0
NCT02039674 Phase Ib/II Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pemetrexed Disodium Ipilimumab + Pembrolizumab Erlotinib + Pembrolizumab Gefitinib + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) Completed 0
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT02043665 Phase I Coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Completed USA | GBR | AUS 0
NCT02044601 Phase Ib/II Carboplatin + Onartuzumab + Paclitaxel Carboplatin + Erlotinib + Onartuzumab + Paclitaxel Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) Withdrawn USA 0
NCT02045446 Phase II Bevacizumab + Erlotinib Docetaxel + Gemcitabine Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02047344 Phase II Antroquinonol Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC Completed USA 1
NCT02066636 Phase III Nivolumab A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) Completed USA | CAN 0
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT02075840 Phase III Alectinib Crizotinib A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 22
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed USA | ESP 0
NCT02080078 Phase I Erlotinib + Theophylline A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Terminated CAN 0
NCT02085070 Phase II Pembrolizumab MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Completed USA 0
NCT02087176 Phase II Adavosertib Pegfilgrastim A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer Terminated USA 0
NCT02087241 Phase II Adavosertib Carboplatin + Pemetrexed Disodium Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer Terminated USA 0
NCT02087423 Phase II Durvalumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 9
NCT02088112 Phase I Durvalumab + Gefitinib MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). Completed USA 2
NCT02091999 Phase I Enfortumab vedotin-ejfv A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Completed USA | CAN 0
NCT02094573 Phase II Brigatinib A Phase 2, Multicenter, Randomized Study of AP26113 Completed 0
NCT02106546 Phase III Veliparib Carboplatin + Paclitaxel Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 29
NCT02108964 Phase Ib/II Nazartinib A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies Completed USA | ESP | DEU | CAN 5
NCT02109016 Phase II Lucitanib A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer Terminated USA | ITA | FRA | ESP | DEU 0
NCT02113813 Phase I Naquotinib A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Completed USA 0
NCT02115464 Phase II Metformin Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy Terminated CAN 0
NCT02117024 Phase II Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Terminated USA 0
NCT02119650 Phase II Cisplatin + Pemetrexed Disodium + Ruxolitinib Cisplatin + Pemetrexed Disodium Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Terminated USA 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed USA 0
NCT02125461 Phase III Durvalumab A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT02132598 Phase II Cabozantinib Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases Terminated USA 0
NCT02133196 Phase II Aldesleukin + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Recruiting USA 0
NCT02134015 Phase III Erlotinib Erlotinib + Patritumab Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Terminated USA | ITA | GBR | ESP | DEU | CAN | BEL 3
NCT02134886 Phase I Erlotinib Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection Terminated USA 0
NCT02134912 Phase II Crizotinib + Pemetrexed Disodium Pemetrexed Disodium S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Terminated USA 0
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed 0
NCT02143466 Phase I Osimertinib + Savolitinib Osimertinib + Selumetinib Durvalumab + Osimertinib AZD9291 in Combination With Ascending Doses of Novel Therapeutics Active, not recruiting USA | CAN 6
NCT02147990 Phase II Rociletinib TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) Terminated USA | GBR | FRA | ESP | DEU | CAN | AUS 5
NCT02151981 Phase III Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Osimertinib AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 10
NCT02152631 Phase III Erlotinib Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 14
NCT02157792 Phase I Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine M6620 First in Human Study Completed USA | GBR 0
NCT02157883 Phase I Osimertinib Itraconazole + Osimertinib Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Completed USA | GBR | BEL 3
NCT02163733 Phase I Osimertinib Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Completed GBR | FRA | ESP 1
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated USA 0
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 1
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02179671 Phase II Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed USA 0
NCT02183883 Phase II Afatinib Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1) Completed GBR 0
NCT02186301 Phase II Rociletinib Erlotinib TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy Terminated USA | ITA | ESP | DEU 3
NCT02186847 Phase II Metformin Carboplatin + Paclitaxel Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting USA | CAN 1
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT02192541 Phase I Aflibercept + Ganetespib Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated USA 0
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated USA 0
NCT02193282 Phase III Erlotinib Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Active, not recruiting USA 1
NCT02194738 Phase I Nivolumab Crizotinib Erlotinib Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting USA 2
NCT02197234 Phase I Osimertinib + Simvastatin Simvastatin Osimertinib Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC Active, not recruiting USA | FRA | ESP | BEL 1
NCT02197247 Phase I Osimertinib + Rifampin Osimertinib Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC Completed USA | GBR | ESP 3
NCT02201992 Phase III Crizotinib Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Recruiting USA 2
NCT02206763 Phase I Erlotinib + Momelotinib Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT02220894 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Completed 0
NCT02221739 Phase II Ipilimumab Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02222922 Phase I Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Completed USA | ESP 0
NCT02225405 Phase I Cisplatin + Docetaxel + Nintedanib Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC) Active, not recruiting USA 0
NCT02228369 Phase I Osimertinib AZD3759 Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM) Completed USA | AUS 2
NCT02250326 Phase II Azacitidine + Nab-paclitaxel Nab-paclitaxel Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN 0
NCT02257619 Phase II Docetaxel Itacitinib Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Terminated USA 0
NCT02258607 Phase I Momelotinib Momelotinib + Trametinib Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase Terminated USA 0
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed 0
NCT02259582 Phase II Carboplatin + Pemetrexed Disodium Demcizumab A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer Completed USA | ITA | ESP | BEL | AUS 0
NCT02259621 Phase II Nivolumab Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC Active, not recruiting USA | CAN 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 2
NCT02264990 Phase III Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers Completed USA | GBR | ESP | DEU | CAN | AUS 14
NCT02271139 Phase III Alectinib Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib No longer available USA 0
NCT02271906 Phase II Afatinib The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting Terminated USA 0
NCT02272413 Phase III Carboplatin + Paclitaxel Bevacizumab Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer Completed USA | ITA | GBR | ESP | DEU 23
NCT02273375 Phase III Durvalumab Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC Active, not recruiting USA | ITA | FRA | ESP | CAN | AUS 13
NCT02277457 Phase I Crizotinib Erlotinib Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations Withdrawn USA 0
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed USA 0
NCT02283320 Phase II Docetaxel A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Completed USA 1
NCT02289833 Phase II Ado-trastuzumab emtansine A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed USA | ITA | ESP | DEU 3
NCT02292550 Phase Ib/II Ceritinib + Ribociclib Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. Completed USA | ITA | FRA | ESP 2
NCT02296125 Phase III Erlotinib Osimertinib Gefitinib AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 21
NCT02298153 Phase I Atezolizumab + Epacadostat A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Terminated USA 0
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT02299505 Phase I Ceritinib Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) Completed USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed USA 0
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed USA | ITA | FRA | ESP | CAN | BEL | AUT | AUS 1
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed USA 0
NCT02309892 Phase I Carboplatin + L-DOS47 + Pemetrexed Disodium A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC Completed USA 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02314364 Phase II A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC Completed USA 0
NCT02314481 Phase II Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) Active, not recruiting GBR 0
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA | FRA 2
NCT02316002 Phase II Pembrolizumab Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer Completed USA 0
NCT02317016 Phase I Osimertinib Rosuvastatin Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer Completed USA | GBR | FRA | ESP 0
NCT02318368 Phase II Erlotinib Erlotinib + Ficlatuzumab A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label Terminated USA | ITA | AUS 4
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Completed USA 0
NCT02321293 Phase I Erlotinib + Gefitinib A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC Unknown status CAN 0
NCT02321501 Phase I Ceritinib + Everolimus Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02321540 Phase Ib/II Ibrutinib A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer Completed USA 0
NCT02322281 Phase III Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated USA | ITA | GBR | FRA | ESP | DEU | AUS 3
NCT02323126 Phase II Nazartinib + Nivolumab Capmatinib + Nivolumab Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer Terminated USA | ITA | FRA | ESP | DEU | AUS 2
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA | GBR 0
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed USA 0
NCT02335944 Phase Ib/II Capmatinib + Nazartinib Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. Terminated USA | ITA | FRA | ESP | DEU | CAN | AUS 4
NCT02336451 Phase II Ceritinib A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT02337530 Phase II Selumetinib Cisplatin + Pemetrexed Disodium Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer Completed CAN 0
NCT02342353 Phase Ib/II Erlotinib + Pacritinib Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) Terminated USA 0
NCT02343952 Phase II Pembrolizumab Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Completed USA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02349633 Phase II Avelumab + Mavelertinib Mavelertinib + Palbociclib Mavelertinib Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) Terminated USA | AUS 2
NCT02350764 Phase II Ipilimumab + Nivolumab Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs Completed USA 0
NCT02352948 Phase III Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT02355431 Phase II Erlotinib Itacitinib INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations Withdrawn USA 0
NCT02357836 Phase I Itraconazole Neoadjuvant Itraconazole in Non-small Cell Lung Cancer Completed USA 0
NCT02364609 Phase I Afatinib + Pembrolizumab Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Completed USA 0
NCT02364999 Phase III Bevacizumab + Carboplatin + Paclitaxel A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC Completed USA | ITA | FRA | ESP | DEU | AUS 21
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA | ESP 0
NCT02366143 Phase III Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Nab-paclitaxel Atezolizumab + Carboplatin + Paclitaxel TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT02367781 Phase III Atezolizumab Carboplatin + Nab-paclitaxel A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer Completed USA | ITA | FRA | ESP | DEU | CAN | BEL 1
NCT02367794 Phase III Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Completed USA 0
NCT02382406 Phase Ib/II Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Terminated USA 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02387216 Phase II Seribantumab Pemetrexed Disodium Docetaxel A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Terminated USA | FRA | ESP | DEU | CAN 1
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed USA 0
NCT02392507 Phase II Carboplatin + Nab-paclitaxel + Necitumumab A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC Completed USA 0
NCT02393625 Phase I Ceritinib + Nivolumab Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Active, not recruiting USA | ITA | ESP | CAN | BEL | AUS 2
NCT02395172 Phase III Avelumab Docetaxel Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Completed USA | ITA | GBR | FRA | ESP | BEL | AUS 22
NCT02400814 Phase I Atezolizumab MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer Terminated USA 0
NCT02403193 Phase Ib/II Spartalizumab + Taminadenant Taminadenant Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) Completed USA 0
NCT02403271 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed USA 0
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | CAN 8
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Completed USA 0
NCT02409342 Phase III Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | ITA | GBR | FRA | ESP | DEU 13
NCT02409355 Phase III Carboplatin Cisplatin Gemcitabine Atezolizumab A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Terminated USA | ITA | GBR | FRA | ESP | DEU 8
NCT02411448 Phase III Erlotinib Gefitinib + Ramucirumab Erlotinib + Ramucirumab Osimertinib + Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 7
NCT02412371 Phase II Veliparib Carboplatin + Paclitaxel A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer Terminated USA 0
NCT02414139 Phase II Capmatinib Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT 12
NCT02414269 Phase I Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Active, not recruiting USA 0
NCT02422381 Phase Ib/II Gemcitabine Pembrolizumab MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02422589 Phase I Warfarin Midazolam Ceritinib A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors Completed USA | ITA | ESP 1
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed USA | ESP 0
NCT02424617 Phase Ib/II Bemcentinib + Erlotinib A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Completed USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02435121 Phase II SAR125844 A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Completed BEL 0
NCT02437136 Phase Ib/II Entinostat + Pembrolizumab Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma Completed USA 0
NCT02438722 Phase II Afatinib Afatinib + Cetuximab S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02439450 Phase I HS-110 Nivolumab A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Completed USA 0
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Completed USA | GBR | FRA | ESP | DEU 1
NCT02444741 Phase Ib/II Pembrolizumab MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02448251 Phase I Abivertinib Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer Terminated USA | FRA | ESP 0
NCT02448303 Phase II Acalabrutinib Pembrolizumab Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer Completed USA 0
NCT02450539 Phase II Abemaciclib Docetaxel A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Completed USA | ITA | FRA | ESP | DEU | AUS 7
NCT02451852 Phase I Osimertinib AZD9291 US Expanded Access Program No longer available USA 0
NCT02451865 Phase I Binimetinib + Docetaxel Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer Withdrawn USA 0
NCT02451930 Phase I Necitumumab Pembrolizumab A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Completed USA | FRA | ESP 1
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02453282 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT02454842 Phase II TH-4000 Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC Terminated USA | AUS 0
NCT02454933 Phase III Osimertinib Durvalumab Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL) Completed CAN 2
NCT02460224 Phase Ib/II Ieramilimab Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT02460367 Phase Ib/II Docetaxel + Indoximod Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer Terminated USA 0
NCT02463994 Phase I Atezolizumab A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC Completed USA 0
NCT02468661 Phase I Capmatinib Capmatinib + Erlotinib Erlotinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Terminated USA | ITA | FRA | ESP | DEU | BEL 4
NCT02469701 Phase II Nivolumab BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease Terminated USA 0
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02474355 Phase III Osimertinib Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Completed ITA | GBR | ESP | CAN | BEL | AUT | AUS 9
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Completed USA 0
NCT02475382 Expanded access Nivolumab Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) No longer available CAN 1
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 23
NCT02485652 Phase II Olmutinib Phase II Trial of HM61713 for the Treatment of >= 2nd Line T790M Mutation Positive Adenocarcinoma of the Lung Terminated USA | ITA | ESP | DEU | CAN | AUS 4
NCT02486718 Phase III Atezolizumab Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Active, not recruiting USA 0
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Completed USA 0
NCT02492867 Phase 0 Durvalumab Carboplatin + Paclitaxel A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT02495636 Phase II Atezolizumab + Rasdegafusp alfa Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer Withdrawn USA 0
NCT02496663 Phase I Necitumumab + Osimertinib Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Active, not recruiting USA 0
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02500199 Phase I Pyrotinib Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Unknown status USA 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Completed USA | ESP 1
NCT02503722 Phase I Osimertinib + Sapanisertib Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT02504372 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) Active, not recruiting 0
NCT02504489 Phase III Docetaxel Docetaxel + Plinabulin Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) Completed USA | AUS 1
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Completed USA | ESP | DEU | BEL | AUT | AUS 3
NCT02511106 Phase III Osimertinib AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT02511184 Phase I Crizotinib Pembrolizumab Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients Terminated USA 0
NCT02514174 FDA approved Afatinib Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Completed USA 0
NCT02516813 Phase I Peposertib Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Completed USA | DEU | BEL 5
NCT02520778 Phase I Navitoclax + Osimertinib Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02521051 Phase Ib/II Bevacizumab Alectinib Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Unknown status USA 0
NCT02523469 Phase Ib/II ALT-803 + Nivolumab ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer Completed USA 0
NCT02525757 Phase II Atezolizumab Carboplatin + Paclitaxel MPDL3280A With Chemoradiation for Lung Cancer Active, not recruiting USA 0
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | FRA | CAN 1
NCT02535338 Phase Ib/II Erlotinib + Onalespib Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02537561 Phase I Talazoparib Cisplatin + Gemcitabine Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors Withdrawn 0
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02542293 Phase III Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE) Active, not recruiting USA | GBR 27
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated USA 0
NCT02544633 Phase II Glesatinib Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET Completed USA | ITA | GBR | CAN | AUS 4
NCT02546986 Phase II Azacitidine + Pembrolizumab Pembrolizumab Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting USA | ITA | FRA | ESP | DEU 1
NCT02547675 Phase I Rociletinib Rociletinib (CO-1686) USA Expanded Access Program No longer available USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Terminated USA | GBR | FRA | CAN | AUS 3
NCT02563548 Phase I PEGPH20 + Pembrolizumab Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab Completed USA 0
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 8
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Completed USA | ITA | FRA | ESP | DEU 3
NCT02573259 Phase I PF-06801591 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Completed USA 6
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Completed USA 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP 1
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | FRA | ESP | DEU 14
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin Avelumab in First-line NSCLC (JAVELIN Lung 100) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 33
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02578680 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Completed 0
NCT02580708 Phase Ib/II Trametinib Rociletinib A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT02581787 Phase Ib/II Fresolimumab SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Completed USA 0
NCT02581943 Phase II Paclitaxel Pembrolizumab Carboplatin Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Completed USA 0
NCT02584634 Phase I Crizotinib Avelumab Lorlatinib Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Terminated USA | ESP | AUS 2
NCT02588261 Phase III Naquotinib Gefitinib Erlotinib A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT02589522 Phase I Berzosertib VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT02591615 Phase II Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Completed USA 0
NCT02592577 Phase I MAGE A10c796T for Advanced NSCLC Completed USA | GBR | ESP | CAN 0
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Active, not recruiting USA 0
NCT02595944 Phase III Nivolumab Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) Active, not recruiting USA 0
NCT02599454 Phase I Atezolizumab Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02605746 Phase I Ceritinib Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis Completed USA 0
NCT02608268 Phase Ib/II Spartalizumab Sabatolimab Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Terminated USA | ITA | CAN 6
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Active, not recruiting USA 0
NCT02609776 Phase I Amivantamab-vmjw Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Lazertinib Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) Active, not recruiting USA | GBR | FRA | ESP | CAN | AUS 4
NCT02616393 Phase II Tesevatinib Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases Completed USA 0
NCT02621398 Phase I Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02630186 Phase Ib/II Atezolizumab + Rociletinib A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC Terminated USA 0
NCT02635061 Phase I Citarinostat + Ipilimumab + Nivolumab Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer Active, not recruiting USA 0
NCT02637531 Phase I Pembrolizumab Eganelisib A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Active, not recruiting USA 0
NCT02638090 Phase Ib/II Pembrolizumab Vorinostat Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Completed USA 0
NCT02639091 Phase I Anetumab ravtansine + Cisplatin + Pemetrexed Disodium Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Completed USA | ITA 0
NCT02639234 Phase II FANG vaccine + Nivolumab Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer Withdrawn USA 0
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Unknown status USA 0
NCT02642042 Phase II Docetaxel + Trametinib Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02642939 Phase II Mifepristone Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Terminated USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02648724 Phase Ib/II SYM015 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Completed USA | ESP 4
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02654587 Phase III OSE 2101 Pemetrexed Disodium Docetaxel Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) Terminated USA | ITA | GBR | FRA | ESP | DEU 4
NCT02658097 Phase II Pembrolizumab A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Completed USA 0
NCT02659059 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) Completed USA | CAN 0
NCT02664181 Phase II Nivolumab Decitabine + Nivolumab + Tetrahydrouridine Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) Active, not recruiting USA 0
NCT02665416 Phase I RO5520985 + Selicrelumab Bevacizumab + Selicrelumab Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Completed USA | ITA | ESP | CAN | BEL 2
NCT02666105 Phase II Exemestane Exemestane in Post-Menopausal Women With NSCLC Completed USA 0
NCT02669914 Phase II Durvalumab MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Terminated USA 0
NCT02671955 Phase I Onvatilimab A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02681549 Phase II Bevacizumab + Pembrolizumab Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Recruiting USA 0
NCT02684461 Phase II Pembrolizumab Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel Completed USA 0
NCT02695290 Phase III Afatinib Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) Terminated USA 0
NCT02696993 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated 0
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Terminated USA 0
NCT02706626 Phase II Brigatinib Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Terminated USA 0
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Terminated USA 0
NCT02713529 Phase Ib/II AMG 820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Completed USA | ESP | DEU | CAN | BEL | AUS 0
NCT02713828 Phase Ib/II Glembatumumab vedotin Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Terminated USA 0
NCT02713867 Phase III Nivolumab A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) Completed USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS 0
NCT02715284 Phase I Dostarlimab-gxly A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting USA | ITA | GBR | FRA | ESP | CAN 7
NCT02716038 Phase II Atezolizumab + Carboplatin + Nab-paclitaxel Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Completed USA 0
NCT02716116 Phase Ib/II Mobocertinib A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | ESP | DEU 5
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Completed USA 0
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Completed USA | ITA | FRA | ESP | CAN | AUS 3
NCT02730247 Phase II Nab-paclitaxel + Ramucirumab Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02733250 Phase Ib/II Nab-paclitaxel + Pembrolizumab Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) Completed CAN 0
NCT02737501 Phase III Brigatinib Crizotinib ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 10
NCT02740985 Phase I AZD4635 AZD4635 + Durvalumab A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies Completed USA 0
NCT02750215 Phase II Capmatinib A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Completed USA 0
NCT02750514 Phase II Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab Linrodostat + Nivolumab An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) Terminated USA | ITA | FRA | ESP | CAN | AUT | AUS 1
NCT02767804 Phase III Crizotinib Ensartinib eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 12
NCT02768558 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Nivolumab Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC Terminated USA 0
NCT02770014 Phase II Erlotinib Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Terminated USA 0
NCT02775435 Phase III Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Completed 0
NCT02779751 Phase II Abemaciclib + Pembrolizumab A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Active, not recruiting USA | ITA | FRA | ESP | BEL 2
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | FRA | CAN 1
NCT02784158 Phase I Brigatinib An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer No longer available USA 0
NCT02789345 Phase I Osimertinib + Ramucirumab Necitumumab + Osimertinib A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Completed USA | FRA | ESP 2
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed USA 0
NCT02803203 Phase Ib/II Bevacizumab + Osimertinib Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers Completed USA 0
NCT02805660 Phase Ib/II Durvalumab + Mocetinostat Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC Terminated USA 0
NCT02812667 Phase I Nivolumab + Plinabulin Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02818426 Phase Ib/II UCPVax Universal Cancer Peptide-based Vaccination in Metastatic NSCLC (UCPVax) Active, not recruiting FRA 0
NCT02818920 Phase II Pembrolizumab Neoadjuvant Pembrolizumab Active, not recruiting USA 0
NCT02823990 Phase II MVA-MUC1-IL2 vaccine + Nivolumab TG4010 and Nivolumab in Patients With Lung Cancer Completed USA 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | FRA | ESP | BEL | AUS 1
NCT02826161 Phase III Napabucasin + Paclitaxel Paclitaxel A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) Terminated USA 0
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Completed ESP 1
NCT02831491 Phase II Docetaxel + Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer Withdrawn 0
NCT02831933 Phase II AdV-tk + Nivolumab Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN) Terminated USA 0
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated USA | ITA | GBR | ESP 0
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed USA 0
NCT02840994 Phase Ib/II CV301 + Nivolumab Nivolumab A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer Completed USA 0
NCT02846792 Phase Ib/II Nivolumab + Plinabulin Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer Terminated USA 0
NCT02848651 Phase II Atezolizumab A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] Completed USA 0
NCT02855125 Phase II Tegafur-gimeracil-oteracil Potassium TAS-114 + Tegafur-gimeracil-oteracil Potassium A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Completed USA | ITA | FRA | ESP 2
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Completed USA | FRA | AUS 1
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Active, not recruiting USA 0
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed USA | DEU 0
NCT02864251 Phase III Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) Completed USA | FRA | ESP | CAN 6
NCT02869789 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT02879617 Phase II Durvalumab A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Completed USA 0
NCT02879760 Phase Ib/II Ad-MAGEA3 + MG1-MAGEA3 + Pembrolizumab Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients Completed CAN 0
NCT02879994 Phase II Pembrolizumab Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Completed USA | GBR | ESP | DEU 3
NCT02897375 Phase I Cisplatin + Palbociclib Carboplatin + Palbociclib Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Completed USA 0
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed USA 0
NCT02898116 Phase Ib/II Durvalumab + Ensartinib Ensartinib A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer Completed USA 0
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Completed USA | ITA | FRA | ESP | CAN | BEL 3
NCT02904954 Phase II Durvalumab Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer Completed USA 0
NCT02912949 Phase Ib/II Zenocutuzumab A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 9
NCT02917993 Phase Ib/II Itacitinib + Osimertinib An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Active, not recruiting USA | ESP 2
NCT02919449 Phase I Atezolizumab + MV-NIS Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer Terminated USA 0
NCT02920450 Phase Ib/II Carboplatin + Gedatolisib + Paclitaxel Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) Terminated USA 0
NCT02920996 Phase II Merestinib Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Active, not recruiting USA 0
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting USA 0
NCT02922777 Phase I Bemcentinib + Docetaxel Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. Completed USA 0
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP 1
NCT02926768 Phase Ib/II CK-101 Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Completed USA | AUS 3
NCT02927301 Phase II Atezolizumab A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02927340 Phase II Lorlatinib A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions Unknown status USA 0
NCT02941601 Phase II Carboplatin + Gemcitabine + Necitumumab A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Withdrawn USA | ITA | GBR | DEU | BEL 2
NCT02942095 Phase I Erlotinib + Ixazomib Study of Ixazomib and Erlotinib in Solid Tumors Completed USA 0
NCT02944396 Phase II Carboplatin + Paclitaxel + Pemetrexed Disodium + Veliparib Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Veliparib Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | ITA | DEU | CAN | AUT 4
NCT02947386 Phase Ib/II Nimotuzumab + Nivolumab Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer Completed USA 0
NCT02949843 Phase II Nivolumab + Pembrolizumab Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Terminated USA 0
NCT02950038 Phase II Ibrutinib + Nivolumab Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Withdrawn 0
NCT02952248 Phase I Ezabenlimab A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Completed USA | GBR | CAN 0
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Completed USA 0
NCT02952989 Phase I SGN-2FF A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Terminated USA 0
NCT02954523 Phase Ib/II Dasatinib + Osimertinib Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Unknown status USA 0
NCT02954991 Phase II Nivolumab + Sitravatinib Mocetinostat + Nivolumab Glesatinib + Nivolumab Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Completed USA 0
NCT02955290 Phase Ib/II CIMAvax-EGF + Nivolumab CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Recruiting USA 0
NCT02955758 Phase II Pembrolizumab Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02959437 Phase Ib/II Azacitidine + Epacadostat + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Terminated USA | GBR | ESP 0
NCT02963610 Phase Ib/II Lenalidomide + Pembrolizumab Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Terminated USA 0
NCT02965885 Phase I Pimitespib A Study of TAS-116 in Patients With Solid Tumors Completed USA | ITA | GBR 0
NCT02967133 Phase II Nab-paclitaxel + Nivolumab Nivolumab A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Terminated USA 0
NCT02971501 Phase II Osimertinib Bevacizumab + Osimertinib Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases Active, not recruiting USA 0
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUS 4
NCT02978404 Phase II Nivolumab Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Active, not recruiting CAN 0
NCT02981108 Phase Ib/II Aumolertinib A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Active, not recruiting USA 0
NCT02983045 Phase Ib/II Nivolumab + NKTR-214 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) Completed USA | ITA | GBR | FRA | ESP | CAN | BEL 1
NCT02983578 Phase II Danvatirsen + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Active, not recruiting USA 0
NCT02987998 Phase I Cisplatin + Etoposide + Pembrolizumab Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC Terminated USA 0
NCT02991651 Phase I Erlotinib + IRX4204 Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC Suspended USA 0
NCT02992912 Phase II Atezolizumab Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) Unknown status FRA 0
NCT02994576 Phase II Atezolizumab Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (PRINCEPS) Completed FRA 0
NCT02998528 Phase III Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) Active, not recruiting USA | ITA | FRA | ESP | CAN 10
NCT03001882 Phase II Ipilimumab + Nivolumab An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Completed USA | ITA | FRA | ESP | DEU | BEL 2
NCT03003468 Phase Ib/II Pembrolizumab + PGG beta-glucan Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 Active, not recruiting USA 0
NCT03003962 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) Active, not recruiting USA | AUS 10
NCT03004105 Phase II Durvalumab + Selumetinib MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Withdrawn 0
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) Completed USA 0
NCT03014648 Phase II Atezolizumab Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT03023319 Phase I Bosutinib + Pemetrexed Disodium Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Completed USA 0
NCT03023423 Phase Ib/II Atezolizumab + Daratumumab Atezolizumab A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) Completed USA | FRA | ESP 2
NCT03023904 Phase II Nivolumab Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads Withdrawn 0
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL 6
NCT03041181 Phase II Docetaxel + Nivolumab Docetaxel Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab Terminated USA 0
NCT03042013 Phase II Naquotinib A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study Withdrawn 0
NCT03048136 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) Withdrawn USA | DEU | CAN 2
NCT03048500 Phase II Metformin + Nivolumab Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Unknown status USA 0
NCT03049618 Phase II Pembrolizumab + sEphB4-HSA Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Active, not recruiting USA 0
NCT03050060 Phase II Nelfinavir + Nivolumab Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Terminated USA 0
NCT03050554 Phase Ib/II Avelumab Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03052608 Phase III Lorlatinib Crizotinib A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT03054038 Phase I Afatinib + Necitumumab Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer Terminated USA 0
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting CAN | AUS 0
NCT03064854 Phase I Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL 5
NCT03066206 Phase II Poziotinib Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Active, not recruiting USA 0
NCT03071757 Phase I ABBV-368 ABBV-368 + Nivolumab A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 3
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03082300 Phase I Naquotinib A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations Terminated USA 0
NCT03083808 Phase II Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Phase II Trial of Continuation Therapy in Advanced NSCLC Completed USA 0
NCT03086733 Phase II Metformin Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore) Completed CAN 0
NCT03087448 Phase Ib/II Ceritinib + Trametinib Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03087760 Phase II Pembrolizumab Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer Completed USA 0
NCT03088930 Phase II Crizotinib Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Completed USA 0
NCT03090737 Phase II Nivolumab Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) Completed USA | CAN 3
NCT03093116 Phase Ib/II Repotrectinib A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT03095612 Phase Ib/II Docetaxel + Selinexor Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Completed USA | ITA | FRA | ESP | DEU | CAN | AUS 2
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Active, not recruiting USA | FRA | ESP 4
NCT03101839 Phase I AZD4785 Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Completed USA | GBR 0
NCT03102242 Phase II Atezolizumab Atezolizumab Immunotherapy in Patients With Advanced NSCLC Completed USA 0
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Completed USA 3
NCT03110978 Phase II Nivolumab Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR Active, not recruiting USA 0
NCT03121417 Phase II Nivolumab Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer Withdrawn USA 0
NCT03122717 Phase I Gefitinib + Osimertinib Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Active, not recruiting USA 0
NCT03123783 Phase Ib/II Nivolumab + Sotigalimab CD40 Agonistic Antibody APX005M in Combination With Nivolumab Completed USA | ESP 0
NCT03130764 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC Withdrawn 0
NCT03131037 Phase I AdV-tk + Valacyclovir Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03131206 Phase Ib/II Alectinib A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Terminated USA 0
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03137771 Phase II Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Active, not recruiting USA | CAN 2
NCT03138889 Phase Ib/II NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors Terminated USA | FRA | ESP | DEU | AUS 0
NCT03141359 Phase II Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Active, not recruiting USA 0
NCT03148327 Phase Ib/II Durvalumab Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy Active, not recruiting USA | AUS 0
NCT03156114 Phase I Ezabenlimab Miptenalimab This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Completed USA | GBR | ESP | CAN 1
NCT03157128 Phase Ib/II Selpercatinib A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT03158129 Phase II Nivolumab Ipilimumab + Nivolumab Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection Active, not recruiting USA 0
NCT03158883 Phase I Avelumab UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients Completed USA 0
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Active, not recruiting USA | GBR | DEU 16
NCT03164772 Phase Ib/II BI 1361849 + Durvalumab + Tremelimumab Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC Completed USA 0
NCT03166254 Phase I Pembrolizumab Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer Withdrawn 0
NCT03166631 Phase I BI 891065 + Ezabenlimab BI 891065 A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Terminated USA 0
NCT03168464 Phase Ib/II Nivolumab Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Terminated USA 0
NCT03170206 Phase Ib/II Palbociclib Binimetinib Binimetinib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Recruiting USA 0
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 6
NCT03177291 Phase I Carboplatin + Pemetrexed Disodium + Pirfenidone Carboplatin + Paclitaxel + Pirfenidone Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Active, not recruiting USA 0
NCT03178071 Expanded access Lorlatinib Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations No longer available USA 0
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 22
NCT03179436 Phase Ib/II MK-1308 + Pembrolizumab MK-1308 Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) Active, not recruiting USA | ITA | FRA | ESP | CAN | AUS 10
NCT03181308 Phase I Carotuximab + Nivolumab Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Completed USA 0
NCT03184571 Phase II Bemcentinib + Pembrolizumab BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC Completed USA | GBR | ESP 1
NCT03191149 Phase II Osimertinib Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Recruiting USA 0
NCT03191786 Phase III Atezolizumab Gemcitabine Vinorelbine A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) Completed ITA | GBR | ESP | DEU | CAN | BEL 18
NCT03195491 Phase III Nivolumab A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) Completed 2
NCT03197467 Phase II Pembrolizumab Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN) Completed DEU 0
NCT03202940 Phase Ib/II Alectinib + Cobimetinib A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC Recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting FRA | ESP | AUS 6
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT03217071 Phase II Pembrolizumab Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer Completed USA 0
NCT03217669 Phase I Epacadostat + Sirolimus Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy Active, not recruiting USA 0
NCT03220477 Phase I Guadecitabine + Mocetinostat + Pembrolizumab Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. Active, not recruiting USA 0
NCT03223155 Phase I Ipilimumab + Nivolumab Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Completed USA 0
NCT03225664 Phase Ib/II Pembrolizumab Pembrolizumab + Trametinib BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03228186 Phase II Docetaxel + MLN4924 Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Terminated USA 0
NCT03228667 Phase II ALT-803 + Nivolumab ALT-803 + Pembrolizumab QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy Active, not recruiting USA 0
NCT03232892 Phase II Trametinib Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer Terminated USA 0
NCT03233724 Phase Ib/II Pembrolizumab Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Terminated USA 0
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Active, not recruiting USA 0
NCT03237377 Phase II Durvalumab + Tremelimumab Durvalumab Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT03239340 Phase III Osimertinib A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS) Completed USA | ITA | ESP 2
NCT03242915 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease Active, not recruiting USA 0
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Completed USA | DEU 0
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Terminated 1
NCT03256136 Phase II Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer Completed USA 0
NCT03257722 Phase Ib/II Idelalisib + Pembrolizumab Pembrolizumab + Idelalisib for Lung Cancer Study Terminated USA 0
NCT03260491 Phase I Patritumab deruxtecan U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Active, not recruiting USA | ESP 4
NCT03262779 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. Completed USA 0
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Terminated USA 0
NCT03268057 Phase Ib/II Avelumab + Pepinemab VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer Completed USA 0
NCT03270176 Phase I Avelumab + Xevinapant A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy Completed CAN 2
NCT03274479 Phase I PBF-1129 PBF-1129 in Patients With NSCLC Active, not recruiting USA 0
NCT03275597 Phase I Durvalumab + Tremelimumab Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Terminated USA 0
NCT03285321 Phase II Ipilimumab + Nivolumab Nivolumab Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03285763 FDA approved Atezolizumab A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL) Completed ITA | GBR | ESP 21
NCT03286296 Phase I LZM009 LZM009 to Treat Patients With Advanced Solid Tumors Completed USA 0
NCT03289962 Phase I Autogene cevumeran Atezolizumab + Autogene cevumeran A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Active, not recruiting USA | GBR | ESP | DEU | CAN | BEL 2
NCT03292133 Phase II Gefitinib + Nazartinib A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03299088 Phase I Pembrolizumab + Trametinib Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Active, not recruiting USA 0
NCT03302234 Phase III Pembrolizumab Ipilimumab + Pembrolizumab Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 16
NCT03302247 Phase II Nivolumab Gemcitabine + Nivolumab Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy Terminated USA 0
NCT03307759 Phase I Pembrolizumab Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) Completed CAN | AUS 0
NCT03308942 Phase II Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Completed USA 0
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Completed USA | CAN 0
NCT03311672 Phase II Pembrolizumab T-Cell PET Imaging With [18F]F-AraG in Lung Cancer Withdrawn 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Active, not recruiting USA 0
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Terminated USA | ITA | GBR | ESP | CAN | AUS 2
NCT03318939 Phase II Poziotinib Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Terminated USA | ITA | FRA | ESP | CAN | BEL 2
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Active, not recruiting USA 0
NCT03322540 Phase II Pembrolizumab Epacadostat + Pembrolizumab Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) Completed USA | ITA | GBR | ESP | CAN | AUS 12
NCT03322566 Phase II Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) Completed USA | ITA | GBR | ESP | CAN | AUS 8
NCT03325166 Phase II Pembrolizumab Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Terminated USA 0
NCT03326752 Phase I DV281 Phase 1b Dose Escalation and Dose Expansion Trial Completed USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | GBR | CAN | BEL | AUS 4
NCT03333343 Phase I LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC Active, not recruiting ITA | DEU | CAN 3
NCT03334617 Phase II Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) Active, not recruiting USA | FRA | ESP | DEU | CAN | AUT 2
NCT03337698 Phase Ib/II Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) Recruiting USA | GBR | FRA | ESP | AUS 3
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated USA | ITA | FRA | ESP | BEL 1
NCT03345810 Phase II Gemcitabine + Vinorelbine Carboplatin + Nab-paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Durvalumab + Gemcitabine + Vinorelbine Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (DURATION) Completed DEU 0
NCT03348904 Phase III Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer Terminated USA 0
NCT03353675 Phase II MVA-MUC1-IL2 vaccine + Nivolumab A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | FRA | BEL 1
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03366766 Phase II Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed USA 0
NCT03367819 Phase Ib/II Isatuximab Cemiplimab + Isatuximab Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies Terminated USA | ITA | GBR | FRA 1
NCT03371992 Phase I Nivolumab Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) Unknown status USA 0
NCT03377023 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Active, not recruiting USA 0
NCT03379441 Phase II Pembrolizumab Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC) Unknown status ITA 0
NCT03380871 Phase I Carboplatin + NEO-PV-01 + Pembrolizumab + Pemetrexed Disodium + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer Completed USA 0
NCT03381274 Phase Ib/II AZD4635 + Oleclumab Oleclumab + Osimertinib Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study Active, not recruiting USA 2
NCT03382899 Phase II Pegilodecakin + Pembrolizumab Pembrolizumab Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) Terminated USA 0
NCT03382912 Phase II Nivolumab + Pegilodecakin Nivolumab Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) Terminated USA 0
NCT03383302 Phase Ib/II Nivolumab SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE) Active, not recruiting GBR 0
NCT03386929 Phase Ib/II Avelumab + Axitinib + Palbociclib Survival Prolongation by Rationale Innovative Genomics (SPRING) Terminated USA | ESP 2
NCT03387111 Phase Ib/II Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Unknown status USA 0
NCT03391869 Phase III Ipilimumab + Nivolumab Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Recruiting USA 0
NCT03392246 Phase II Osimertinib + Selumetinib A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Active, not recruiting USA 0
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Completed USA 0
NCT03396497 Phase I LYC-55716 + Pembrolizumab Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Unknown status USA 0
NCT03401385 Phase I Datopotamab deruxtecan First-in-human Study of DS-1062a for Advanced Solid Tumors Recruiting USA 1
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Completed USA 1
NCT03410043 Phase II Osimertinib Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study Active, not recruiting USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Terminated USA | GBR | FRA | ESP 0
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Recruiting USA 0
NCT03415126 Phase I ERAS-007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Completed USA 0
NCT03417037 Phase III Linrodostat + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer Withdrawn USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS 9
NCT03417882 Phase II GRN-1201 + Pembrolizumab GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC Terminated USA 0
NCT03418532 Phase Ib/II MP0250 MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC Terminated USA 0
NCT03419559 Phase II LN-145 Durvalumab + LN-145 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer Withdrawn USA 0
NCT03425006 Phase II Itacitinib + Pembrolizumab Pembrolizumab and Itacitinib (INCB039110) for NSCLC Terminated USA 0
NCT03425279 Phase Ib/II Mecbotamab Vedotin CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA 2
NCT03425331 Phase II Ipilimumab + Nivolumab Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC Suspended USA 0
NCT03425643 Phase III Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 16
NCT03430063 Phase II Cemiplimab + Ipilimumab Cemiplimab A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer Terminated USA | GBR | FRA | ESP | DEU | BEL 3
NCT03433469 Phase II Osimertinib Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Active, not recruiting USA 0
NCT03434418 Phase II Osimertinib A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations Completed USA 0
NCT03435250 Phase I AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Terminated USA | FRA | ESP 0
NCT03438318 Phase I Atezolizumab + Vidutolimod Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer Completed USA 0
NCT03446417 Phase I ZN-e4 A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer Completed USA 1
NCT03447769 Phase III Canakinumab Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 33
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03455556 Phase Ib/II Anetumab ravtansine + Atezolizumab Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer Terminated USA 0
NCT03455829 Phase Ib/II Osimertinib G1T38 + Osimertinib G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Completed USA 0
NCT03456063 Phase III Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS 16
NCT03456076 Phase III Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS 19
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Completed USA 0
NCT03469960 Phase III Ipilimumab + Nivolumab Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE) Active, not recruiting FRA 0
NCT03472560 Phase II Avelumab + Axitinib A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) Terminated USA | ITA | ESP 5
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Completed USA | CAN | AUS 2
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03485209 Phase II Tisotumab vedotin-tftv Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 1
NCT03497767 Phase II Osimertinib A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN) Recruiting AUS 1
NCT03502330 Phase I Cabiralizumab + Nivolumab + Sotigalimab Cabiralizumab + Sotigalimab APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Active, not recruiting USA 0
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA | ITA | ESP | DEU 4
NCT03505710 Phase II Trastuzumab deruxtecan DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01) Active, not recruiting USA | FRA | ESP 2
NCT03509012 Phase I Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Active, not recruiting USA | ESP 3
NCT03515629 Phase III Cemiplimab + Ipilimumab Pembrolizumab REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Terminated USA | ITA 1
NCT03515837 Phase III Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Cisplatin + Pemetrexed Disodium Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT03516214 Phase I Nazartinib + Trametinib EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations (EATON) Completed ESP | DEU 0
NCT03516981 Phase II MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) Active, not recruiting USA | ITA | GBR | ESP | CAN | AUS 10
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03520686 Phase III ALT-803 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab ALT-803 + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. Active, not recruiting USA 0
NCT03520842 Phase II Methotrexate + Regorafenib Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Completed USA 0
NCT03521154 Phase III Osimertinib A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA) Active, not recruiting USA | ESP 15
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Completed USA 0
NCT03526887 Phase II Pembrolizumab Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) Completed ESP 0
NCT03527108 Phase II Nivolumab + Ramucirumab Nivolumab Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Recruiting USA 0
NCT03535363 Phase I Osimertinib Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC Completed USA 0
NCT03535740 Phase II Brigatinib A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS 7
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03539536 Phase II Telisotuzumab vedotin Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT03546361 Phase I Ad-CCL21-DC Ad-CCL21-DC + Pembrolizumab CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer Recruiting USA 0
NCT03559049 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03563716 Phase II Atezolizumab + Tiragolumab Atezolizumab A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Active, not recruiting USA | FRA | ESP 3
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | CAN 4
NCT03567642 Phase I Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Active, not recruiting USA 0
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03573947 Phase II Ipilimumab + Nivolumab + Paclitaxel Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705) Completed USA 0
NCT03574220 Phase I Pembrolizumab Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer Withdrawn 0
NCT03574649 Phase II Carboplatin + Cisplatin + Docetaxel + Paclitaxel Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Withdrawn USA 0
NCT03580694 Phase I Cemiplimab + REGN4659 Cemiplimab Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03581487 Phase Ib/II Durvalumab + Selumetinib + Tremelimumab Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03583086 Phase Ib/II Nivolumab + Vorolanib H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Active, not recruiting USA 0
NCT03586453 Phase II Osimertinib Osimertinib In EGFR Mutant Lung Cancer Recruiting USA 0
NCT03588039 Phase I Oraxol + Pembrolizumab Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT03589547 Phase II Durvalumab Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Active, not recruiting USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA 0
NCT03595059 Phase I Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors Active, not recruiting USA | ESP | CAN | AUS 6
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03596866 Phase III Brigatinib Alectinib A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 13
NCT03600701 Phase II Atezolizumab + Cobimetinib Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting USA 0
NCT03611738 Phase I Ceritinib + Docetaxel Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Active, not recruiting USA 0
NCT03611868 Phase Ib/II APG-115 + Pembrolizumab A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Recruiting USA | AUS 0
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03625323 Phase II Eftilagimod alpha + Pembrolizumab Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) Active, not recruiting USA | GBR | ESP | AUS 1
NCT03626545 Phase III Canakinumab + Docetaxel Docetaxel Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2) Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 18
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03631199 Phase III Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 32
NCT03631706 Phase II Bintrafusp alfa Pembrolizumab M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 11
NCT03631784 Phase II Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). (KEYNOTE-799) Active, not recruiting USA | GBR | FRA | ESP | DEU | AUS 4
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Completed USA 0
NCT03634241 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules Recruiting USA 0
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Terminated USA | BEL 1
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Terminated USA 0
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Completed USA | AUS 0
NCT03645928 Phase II Lifileucel + Pembrolizumab LN-145 LN-145 + Pembrolizumab Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Recruiting USA | GBR | FRA | ESP | DEU | CAN 2
NCT03647163 Phase I Pembrolizumab + VSV-hIFNbeta-NIS Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC Recruiting USA 0
NCT03647488 Phase II Capmatinib + Spartalizumab Docetaxel Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Completed USA | FRA | ESP | DEU | BEL 1
NCT03656627 Phase I Nivolumab Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Terminated USA 0
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Active, not recruiting USA | ITA | GBR | FRA | ESP 7
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN | BEL 0
NCT03663166 Phase Ib/II Cisplatin + Ipilimumab + Pemetrexed Disodium Nivolumab Carboplatin + Ipilimumab + Paclitaxel Cisplatin + Etoposide + Ipilimumab Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03664024 Phase II Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) Completed USA | ESP | CAN 2
NCT03665129 Phase I Avdoralimab + Durvalumab IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) Terminated USA | FRA 0
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Terminated USA | ESP | CAN | AUS 0
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03667820 Phase II Osimertinib Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC Active, not recruiting USA 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting USA | AUS 4
NCT03674827 Phase I PF-06936308 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC Terminated USA 0
NCT03679767 Phase II Retifanlimab A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Completed USA | ITA | FRA | ESP | AUT 3
NCT03681483 Phase I RO5126766 RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Active, not recruiting USA 0
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Terminated USA 0
NCT03689855 Phase II Atezolizumab + Ramucirumab Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1) Active, not recruiting USA 0
NCT03693300 Phase II Durvalumab A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed USA | CAN | AUS 0
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Active, not recruiting USA 0
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03707938 Phase I Brigatinib Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03708328 Phase I RO7121661 A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors Active, not recruiting USA | FRA | ESP 3
NCT03709706 Phase Ib/II NY-ESO-1-c259T + Pembrolizumab NY-ESO-1-c259T Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells Specific in NY-ESO-1/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab Terminated USA | GBR | ESP | CAN 1
NCT03713944 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Terminated USA 0
NCT03735121 Phase III Atezolizumab + rHuPH20 Atezolizumab A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Active, not recruiting ITA | GBR | FRA | ESP 19
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Terminated USA 0
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT03737994 Phase II Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03739710 Phase Ib/II Docetaxel Docetaxel + GSK3359609 Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC) Recruiting USA | ITA | FRA | ESP | DEU | CAN 6
NCT03745222 Phase III Tislelizumab Cisplatin + Etoposide + Tislelizumab Carboplatin + Paclitaxel + Tislelizumab Cisplatin + Etoposide Carboplatin + Paclitaxel A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 15
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03755102 Phase I Dacomitinib A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. Completed USA 0
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Completed USA 0
NCT03769103 Phase II Osimertinib Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC Recruiting CAN 0
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Withdrawn 0
NCT03774732 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG) Recruiting FRA 1
NCT03775486 Phase II Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) Active, not recruiting USA | GBR | BEL 9
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Completed USA | CAN 0
NCT03778229 Phase II Osimertinib + Savolitinib Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) Recruiting USA | ITA | FRA | ESP | CAN 9
NCT03780517 Phase I DS-5010 Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Completed USA | FRA | ESP | BEL 3
NCT03784378 Phase I RXDX-105 Continued Access to RXDX-105 Completed USA 0
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Unknown status ESP 0
NCT03793179 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer Active, not recruiting USA | CAN 1
NCT03794544 Phase II Durvalumab + Oleclumab Danvatirsen + Durvalumab Durvalumab Durvalumab + Monalizumab Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Completed USA | ITA | FRA | ESP | CAN 2
NCT03797391 Phase Ib/II EMB-01 A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT03800134 Phase III Cisplatin + Durvalumab + Gemcitabine Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Gemcitabine A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 20
NCT03801902 Phase I Durvalumab + Monalizumab Durvalumab Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial Recruiting USA 0
NCT03805841 Phase II TH-4000 Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN) Terminated USA | CAN 1
NCT03808558 Phase II TVB-2640 Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas Recruiting USA 0
NCT03809624 Phase II INBRX-105 INBRX-105 + Pembrolizumab Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) Recruiting USA 0
NCT03810066 Phase II Osimertinib Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) Completed DEU 0
NCT03810807 Phase I Dacomitinib + Osimertinib Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer Active, not recruiting USA 0
NCT03815682 Phase I Pembrolizumab + RPTR-147 RPTR-147 RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Terminated USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03818776 Phase I Durvalumab Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC Terminated USA 0
NCT03819387 Phase I NBF-006 A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Active, not recruiting USA 0
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Active, not recruiting USA | ESP | BEL | AUT 5
NCT03822351 Phase II Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) Completed USA | ITA | FRA | ESP | CAN 4
NCT03824327 Phase I Papaverine Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases Suspended USA 0
NCT03827850 Phase II Erdafitinib FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) Terminated DEU 0
NCT03829319 Phase III Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | AUS 10
NCT03829332 Phase III Pembrolizumab Lenvatinib + Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) Active, not recruiting USA | ITA | FRA | CAN | AUS 14
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Active, not recruiting USA | ITA | GBR 3
NCT03831932 Phase Ib/II Osimertinib + Telaglenastat Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer Recruiting USA 0
NCT03833154 Phase III Durvalumab Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT03833440 Phase II Ceralasertib + Durvalumab Durvalumab + Oleclumab Docetaxel Durvalumab + Monalizumab Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR) Recruiting FRA 0
NCT03836352 Phase II Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Active, not recruiting USA | CAN 0
NCT03838159 Phase II Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel NADIM II: Neo-Adjuvant Immunotherapy (NADIMII) Active, not recruiting ESP 0
NCT03840902 Phase II Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Terminated USA | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT03840915 Phase Ib/II Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Completed USA | FRA | BEL 0
NCT03845166 Phase I XL092 A Study of XL092 in Subjects With Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 2
NCT03845296 Phase II Rucaparib Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Active, not recruiting USA 0
NCT03846310 Phase I Carboplatin + Etrumadenant + Pemetrexed Disodium Zimberelimab Carboplatin + Etrumadenant + Pembrolizumab + Pemetrexed Disodium A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Active, not recruiting USA 3
NCT03847519 Phase Ib/II ADXS-503 + Pembrolizumab ADXS-503 Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Unknown status USA 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03867175 Phase III Pembrolizumab Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03875820 Phase I Defactinib + RO5126766 Phase I Trial of Defactinib and VS-6766. (FRAME) Active, not recruiting GBR 0
NCT03891615 Phase I Niraparib + Osimertinib Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer Recruiting USA 0
NCT03891953 Phase I DKY709 DKY709 + Spartalizumab Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Active, not recruiting USA | ESP | DEU 3
NCT03893955 Phase I ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-368 + ABBV-927 + Budigalimab ABBV-927 + Budigalimab + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA | FRA | ESP | AUS 2
NCT03904108 Phase II Ramucirumab Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy Terminated USA 0
NCT03905148 Phase Ib/II Lifirafenib + PD-0325901 Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors Recruiting USA | AUS 0
NCT03907852 Phase Ib/II Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA | CAN 0
NCT03915678 Phase II Atezolizumab + BDB001 Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) Recruiting FRA 0
NCT03915951 Phase II Binimetinib + Encorafenib An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer Active, not recruiting USA | ITA | ESP 2
NCT03916419 Phase II Durvalumab Carboplatin + Paclitaxel Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03916627 Phase II Cemiplimab Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC Recruiting USA 0
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Active, not recruiting USA | ITA | ESP 7
NCT03920839 Phase I Carboplatin + Paclitaxel + Retifanlimab Cisplatin + Gemcitabine + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium + Retifanlimab INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) Withdrawn 0
NCT03924869 Phase III Pembrolizumab Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 15
NCT03934814 Phase I Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Completed USA 1
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03940703 Phase II Osimertinib + Tepotinib Tepotinib A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 11
NCT03948763 Phase I mRNA 5671 mRNA 5671 + Pembrolizumab A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Completed USA | AUS 5
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Completed USA 0
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Terminated USA 0
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) Recruiting USA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Active, not recruiting USA | FRA | ESP | CAN | BEL | AUS 2
NCT03965468 Phase II Carboplatin + Durvalumab + Paclitaxel Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS) Recruiting ITA | ESP 2
NCT03965689 Phase II Carboplatin + MLN4924 + Paclitaxel Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel for Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03965845 Phase Ib/II Palbociclib + Telaglenastat A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Completed USA 0
NCT03968419 Phase II Canakinumab Pembrolizumab Canakinumab + Pembrolizumab This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) Terminated USA | FRA | ESP | DEU | CAN | BEL 6
NCT03970746 Phase Ib/II PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC Active, not recruiting FRA | DEU | BEL 2
NCT03971474 Phase II Docetaxel + Gemcitabine + Pemetrexed Disodium Docetaxel + Ramucirumab Docetaxel + Gemcitabine Pembrolizumab + Ramucirumab Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) Active, not recruiting USA 0
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Terminated USA | GBR | ESP 0
NCT03974022 Phase Ib/II Sunvozertinib Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) Recruiting USA | ITA | FRA | ESP | AUS 4
NCT03976518 Phase II Atezolizumab Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (CHANCE) Completed ITA 0
NCT03977194 Phase III Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY) Active, not recruiting FRA 0
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Active, not recruiting USA 0
NCT03989115 Phase Ib/II Cobimetinib + RMC-4630 Osimertinib + RMC-4630 Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC Completed USA 1
NCT03989362 Phase II Ipilimumab + Vopratelimab Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE) Completed USA | CAN 0
NCT03990233 Phase I Effi-DEM Effi-DEM + Ezabenlimab A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Active, not recruiting FRA | BEL 0
NCT03991819 Phase I Binimetinib + Pembrolizumab Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer Recruiting CAN 0
NCT03993873 Phase Ib/II TPX-0022 Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) Active, not recruiting USA | FRA | ESP 2
NCT03996473 Phase Ib/II Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases Terminated USA | ESP | BEL 1
NCT03999710 Phase II Durvalumab Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT04000529 Phase I Spartalizumab + TNO155 Ribociclib + TNO155 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Terminated USA | ESP | DEU | BEL | AUS 4
NCT04003246 Phase III Durvalumab Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT04005144 Phase I Binimetinib + Brigatinib Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Terminated USA 0
NCT04006301 Phase I JNJ-74699157 First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation Completed USA | FRA 0
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting USA 0
NCT04013542 Phase I Ipilimumab + Nivolumab Nivolumab Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Active, not recruiting USA 0
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Completed USA 0
NCT04022876 Phase I ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Terminated USA | ITA | ESP | DEU 3
NCT04025879 Phase III Carboplatin + Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT04026412 Phase III Nivolumab Ipilimumab + Nivolumab Durvalumab A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 18
NCT04032418 Phase II Pembrolizumab Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Terminated USA | ITA | GBR | AUS 2
NCT04032847 Phase Ib/II ATL001 + Pembrolizumab ATL001 ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC Recruiting USA | GBR | FRA | ESP | DEU 0
NCT04036682 Phase Ib/II Zipalertinib A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1) Recruiting USA 7
NCT04037462 Phase Ib/II Dexamethasone Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy Completed USA 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP 0
NCT04042701 Phase I Pembrolizumab + Trastuzumab deruxtecan DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Recruiting USA | GBR | FRA | ESP 0
NCT04044859 Phase I ADP-A2M4 cells ADP-A2M4 cells + Pembrolizumab ADP-A2M4 cells + Nivolumab ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Recruiting USA | ESP | CAN | BEL 0
NCT04047862 Phase I BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors Active, not recruiting USA | AUS 2
NCT04052971 Phase Ib/II ABN401 To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation Recruiting AUS 1
NCT04061590 Phase II Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Withdrawn USA 0
NCT04062708 Phase II Cisplatin + Docetaxel + Durvalumab Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Active, not recruiting USA 0
NCT04069026 Phase I BAY2416964 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer Completed USA | GBR | ESP | DEU | CAN 0
NCT04069936 Phase II Marrow infiltrating lymphocytes + Pembrolizumab Marrow infiltrating lymphocytes Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs - NSCLC) Alone or in Combination With Pembrolizumab in Advanced Unresectable or Metastatic NSCLC Terminated USA 0
NCT04075396 Phase Ib/II Lazertinib A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Completed USA | GBR | ESP 0
NCT04077099 Phase Ib/II REGN5093 REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer Active, not recruiting USA | FRA 1
NCT04077463 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium Amivantamab-vmjw Lazertinib A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2) Recruiting USA | ITA | FRA | ESP | DEU 5
NCT04081688 Phase I Atezolizumab + Varlilumab Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC Active, not recruiting USA 0
NCT04083599 Phase Ib/II GEN1042 GEN1042 Safety Trial in Subjects With Malignant Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU 6
NCT04092283 Phase III Carboplatin + Paclitaxel Cisplatin + Etoposide Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Paclitaxel Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Active, not recruiting USA 1
NCT04092673 Phase Ib/II Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin) Recruiting USA 0
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Completed USA | GBR | ESP | DEU 1
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04108026 Phase II Durvalumab Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) Active, not recruiting FRA 0
NCT04111705 Phase II Lorlatinib Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) Active, not recruiting FRA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04120454 Phase II Pembrolizumab + Ramucirumab Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04123379 Phase II BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Active, not recruiting USA 0
NCT04127110 Phase II Lorlatinib Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE) Active, not recruiting GBR | FRA | ESP | BEL 3
NCT04129502 Phase III Mobocertinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT04130516 Phase Ib/II LNS8801 LNS8801 + Pembrolizumab Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Recruiting USA 0
NCT04131543 Phase II Cabozantinib Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) Unknown status ITA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04139317 Phase II Capmatinib + Pembrolizumab Pembrolizumab Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50% Terminated ITA | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT04140500 Phase I RO7247669 Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors Recruiting USA | GBR | ESP 10
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04141644 Phase I Ipilimumab + Osimertinib PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Osi+Ipi) Active, not recruiting USA 0
NCT04143789 Phase Ib/II AP-002 Evaluation of AP-002 in Patients With Solid Tumors Unknown status USA 0
NCT04146571 Expanded access Ensartinib Expanded Access to Ensartinib for Participants With ALK+ NSCLC Available USA 0
NCT04151563 Phase Ib/II Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy Withdrawn USA | BEL 8
NCT04157517 Phase I TAK-573 A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study Completed USA | AUS 0
NCT04158700 Phase Ib/II LY3200882 + Pembrolizumab A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer Withdrawn USA | FRA | ESP 0
NCT04165070 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + Vibostolimab Carboplatin + Paclitaxel + Pembrolizumab + Vibostolimab Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naive Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A) Active, not recruiting USA | ITA | ESP 4
NCT04165083 Phase II MK-4830 + Pembrolizumab KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) Active, not recruiting USA | ITA | ESP 4
NCT04165096 Phase II MK-5890 + Pembrolizumab Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYNOTE-01C) Active, not recruiting USA | ITA | ESP 4
NCT04165330 Phase Ib/II Anlotinib + Nivolumab Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Active, not recruiting USA 0
NCT04166487 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium Plasma-Adapted First-Line Pembro In NSCLC Active, not recruiting USA 0
NCT04173338 Phase I Cabozantinib + Pemetrexed Disodium Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Terminated USA 0
NCT04173507 Phase II Avelumab + Talazoparib Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) Active, not recruiting USA 0
NCT04185883 Phase Ib/II Fluorouracil + Irinotecan + Panitumumab + Sotorasib AMG 404 + Sotorasib Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sotorasib Sotorasib + TNO155 Atezolizumab + Sotorasib Pembrolizumab + Sotorasib Sotorasib Everolimus + Sotorasib Bevacizumab-awwb + Fluorouracil + Oxaliplatin + Sotorasib Bevacizumab-awwb + Fluorouracil + Irinotecan + Sotorasib BI 1701963 + Sotorasib Palbociclib + Sotorasib Afatinib + Sotorasib RMC-4630 + Sotorasib Panitumumab + Sotorasib + Trametinib Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 4
NCT04189614 Phase I Cofetuzumab pelidotin An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer Active, not recruiting USA | ESP 4
NCT04197934 Phase I WSD0922 WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases Recruiting USA 0
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04202809 Phase II Durvalumab Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) Recruiting DEU 0
NCT04205552 Phase II Nivolumab + Relatlimab Nivolumab Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict) Recruiting DEU | BEL 1
NCT04205812 Phase III Retifanlimab Pemetrexed Disodium Carboplatin + Nab-paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Nab-paclitaxel + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Retifanlimab Carboplatin + Paclitaxel Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304) Active, not recruiting USA 16
NCT04214262 Phase III Atezolizumab Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Recruiting USA 0
NCT04216316 Phase Ib/II Avelumab + Carboplatin + Gemcitabine Avelumab + Berzosertib + Carboplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatments (Carboplatin and Gemcitabine) and to Avelumab for Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04219254 Phase Ib/II BI-1206 + Pembrolizumab A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT04222972 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 16
NCT04223596 Phase II Brigatinib Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) Active, not recruiting ESP 0
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting USA | CAN 1
NCT04227028 Phase I Bevacizumab + Brigatinib Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC Recruiting USA 0
NCT04233021 Phase II Osimertinib Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) Active, not recruiting FRA 0
NCT04244552 Phase I ATRC-101 First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies Terminated USA 0
NCT04249362 Phase II Durvalumab Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART) Completed USA | ITA | FRA | ESP 2
NCT04249843 Phase I BGB3245 Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors Recruiting USA | AUS 0
NCT04250246 Phase II Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1) Not yet recruiting ITA 0
NCT04250545 Phase I Sapanisertib + Telaglenastat Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04253964 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy Recruiting USA 0
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04262375 Phase II Durvalumab + Oleclumab A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) Withdrawn CAN 0
NCT04262388 Phase II Durvalumab + Oleclumab A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Withdrawn CAN 0
NCT04262869 Phase II Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Durvalumab Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer Withdrawn 0
NCT04263051 Phase II Nivolumab + UCPVax Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax) Active, not recruiting FRA 0
NCT04267237 Phase II Atezolizumab + Autogene cevumeran Atezolizumab A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer Withdrawn 0
NCT04267848 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial Recruiting USA 1
NCT04268550 Phase II Selpercatinib Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Active, not recruiting USA 0
NCT04270591 Phase Ib/II SCC244 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer Recruiting USA 2
NCT04270864 Phase I IMO-2125 + Ipilimumab + Nivolumab Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) Active, not recruiting FRA 0
NCT04272203 Phase I ABBV-184 A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers Terminated USA | GBR | FRA 2
NCT04274907 Phase I Pembrolizumab + Venetoclax Pembrolizumab A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression Terminated USA 0
NCT04276376 Phase II Atezolizumab + Rucaparib Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) Suspended FRA 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04285671 Phase Ib/II Necitumumab + Osimertinib + Trastuzumab Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer Recruiting USA 0
NCT04291105 Phase II Cemiplimab + VSV-hIFNbeta-NIS Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Recruiting USA 1
NCT04292119 Phase Ib/II Binimetinib + Lorlatinib Crizotinib + Lorlatinib Lorlatinib Combinations in Lung Cancer Unknown status USA 0
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Active, not recruiting USA 0
NCT04294810 Phase III Atezolizumab Atezolizumab + Tiragolumab A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) Active, not recruiting USA | ITA | ESP | DEU | AUT | AUS 18
NCT04297605 Phase I Pembrolizumab + Pemetrexed Disodium Nab-paclitaxel + Pembrolizumab Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 Recruiting USA 0
NCT04302025 Phase II Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer Recruiting USA 0
NCT04303780 Phase III Sotorasib Docetaxel Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT04310007 Phase II Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04310020 Phase II Atezolizumab Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients Recruiting USA 0
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Terminated USA | ITA 1
NCT04314089 Phase I GT103 Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) Active, not recruiting USA 0
NCT04317534 Phase II Pembrolizumab Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm Recruiting USA 0
NCT04318938 Phase II Brigatinib Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping Active, not recruiting DEU 0
NCT04323436 Phase II Capmatinib + Spartalizumab Capmatinib Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL 2
NCT04330664 Phase Ib/II Adagrasib + TNO155 Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Active, not recruiting USA 0
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04335292 Phase II Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Osimertinib Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT) Recruiting CAN 0
NCT04340882 Phase II Docetaxel + Pembrolizumab + Ramucirumab Phase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (TaxRamPem) Recruiting USA 0
NCT04348292 Phase I Durvalumab + Sirolimus Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer Terminated USA 0
NCT04349267 Phase Ib/II BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors Active, not recruiting USA | CAN 1
NCT04351256 Phase II Durvalumab Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo) Recruiting DEU 0
NCT04362072 FDA approved Lorlatinib Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | ESP 3
NCT04364048 Phase II Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04364620 Phase II AB-16B5 + Docetaxel AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer Completed USA | CAN 0
NCT04367311 Phase II Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Docetaxel Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors >= 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Recruiting USA 0
NCT04372927 Phase II Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy Terminated USA 0
NCT04380636 Phase III Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 19
NCT04381650 Phase Ib/II Pembrolizumab + Subasumstat A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Recruiting USA 8
NCT04383938 Phase Ib/II APR-246 + Pembrolizumab Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Completed USA 0
NCT04385368 Phase III Durvalumab Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 25
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP 1
NCT04396535 Phase II Bintrafusp alfa + Docetaxel Docetaxel Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer Terminated USA 0
NCT04410796 Phase II Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Recruiting USA 0
NCT04413201 FDA approved Afatinib + Osimertinib Osimertinib AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC Active, not recruiting DEU 0
NCT04418167 Phase I JSI-1187 Dabrafenib + JSI-1187 JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations Suspended USA 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04427072 Phase III Docetaxel Capmatinib Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III) Completed ITA | FRA | ESP | DEU | BEL 5
NCT04432207 Phase I IMU-201 Atezolizumab + IMU-201 A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Active, not recruiting USA | AUS 0
NCT04440735 Phase Ib/II Atezolizumab + DSP107 DSP107 A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors Recruiting USA 0
NCT04441138 Phase II Durvalumab Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205) Recruiting USA 0
NCT04442126 Phase Ib/II NM21-1480 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Terminated USA | ESP 1
NCT04444427 Phase Ib/II GLR2007 Evaluation of GLR2007 for Advanced Solid Tumors Completed USA 0
NCT04449874 Phase I Atezolizumab + Divarasib Bevacizumab + Divarasib Cetuximab + Divarasib Divarasib + Erlotinib Divarasib A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS 11
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT04452214 Phase I Nidanilimab + Pembrolizumab A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors Completed USA 0
NCT04467723 Phase Ib/II Atezolizumab + Pirfenidone Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC Recruiting USA 0
NCT04467801 Phase II Ipatasertib Docetaxel + Ipatasertib Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung) Recruiting USA 0
NCT04471415 Phase Ib/II DRP-104 Atezolizumab + DRP-104 Study to Investigate DRP-104 in Adults With Advanced Solid Tumors Terminated USA | ESP | DEU 2
NCT04471428 Phase III Docetaxel Atezolizumab + Cabozantinib Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 6
NCT04475939 Phase III Pembrolizumab Niraparib + Pembrolizumab Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 19
NCT04479306 Phase I Osimertinib + Sapanisertib Alisertib + Osimertinib Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer Completed USA 0
NCT04484142 Phase II Datopotamab deruxtecan Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) Active, not recruiting USA | ITA | FRA | ESP | DEU 5
NCT04486833 Phase Ib/II Osimertinib + Quaratusugene Ozeplasmid Carboplatin Cisplatin Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) Recruiting USA 0
NCT04487080 Phase III Amivantamab-vmjw + Lazertinib Lazertinib Osimertinib A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 19
NCT04491084 Phase Ib/II CDX-1140 + CDX-301 FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy (FLT3) Terminated USA 0
NCT04491942 Phase I BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04495153 Phase II AdV-tk GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Active, not recruiting USA 0
NCT04499053 Phase II Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer Recruiting USA 0
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Active, not recruiting USA | FRA | ESP | CAN 0
NCT04505839 Phase I STP1002 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Completed USA 0
NCT04511845 Phase I SPYK04 A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Recruiting USA 1
NCT04512430 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients Recruiting ESP 0
NCT04513925 Phase III Atezolizumab + Tiragolumab Durvalumab A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04526509 Phase I Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors Active, not recruiting USA | DEU | CAN | AUS 2
NCT04526691 Phase I Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) Active, not recruiting USA | ITA | ESP 2
NCT04526782 Phase II Docetaxel Binimetinib + Encorafenib ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) Recruiting FRA 0
NCT04533451 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04541407 Phase I Osimertinib + Temozolomide Lorlatinib + Temozolomide Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease Completed USA 0
NCT04543188 Phase I Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement Active, not recruiting USA | CAN 1
NCT04547504 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE) Recruiting FRA 0
NCT04550104 Phase I AZD1390 Olaparib A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE) Recruiting GBR 0
NCT04553133 Phase II PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 PF-07104091 as a Single Agent and in Combination Therapy Recruiting USA 3
NCT04560686 Phase II Bintrafusp alfa Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer Terminated USA 0
NCT04561362 Phase Ib/II BT8009 BT8009 + Pembrolizumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04564157 Phase III Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) Active, not recruiting ESP 0
NCT04580485 Phase I INCB106385 + Retifanlimab INCB106385 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | BEL 0
NCT04585035 Phase Ib/II D-1553 Study to Evaluate D-1553 in Subjects With Solid Tumors Active, not recruiting USA | AUS 2
NCT04585477 Phase II Durvalumab Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) Recruiting USA 0
NCT04585490 Phase III Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Paclitaxel Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Recruiting USA 0
NCT04585815 Phase Ib/II Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591 Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) Active, not recruiting USA | GBR | BEL | AUS 1
NCT04591431 Phase II Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) Active, not recruiting ITA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04597671 Phase III Durvalumab Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28) Recruiting 1
NCT04601402 Phase I Avelumab + GEN-001 GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy Completed USA 0
NCT04603807 Phase III Entrectinib Crizotinib A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Recruiting ITA | FRA | ESP 14
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Recruiting USA | GBR | CAN 1
NCT04606446 Phase I PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) Recruiting USA | AUS 3
NCT04606771 Phase II Savolitinib Osimertinib + Savolitinib A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC) Active, not recruiting USA 5
NCT04609566 Phase II Brentuximab vedotin + Pembrolizumab Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Recruiting USA | CAN 0
NCT04612751 Phase I Datopotamab deruxtecan + Durvalumab AZD2936 + Carboplatin + Datopotamab deruxtecan AZD2936 + Datopotamab deruxtecan Carboplatin + Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + MEDI5752 Carboplatin + Datopotamab deruxtecan + MEDI5752 Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) Recruiting USA | ITA | FRA | ESP | BEL 5
NCT04613596 Phase II Adagrasib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Adagrasib Carboplatin + Pembrolizumab + Pemetrexed Disodium Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 Recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT04614103 Phase II LN-145 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Recruiting USA | DEU | CAN 1
NCT04619004 Phase II Patritumab deruxtecan HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 7
NCT04620330 Phase II Defactinib + RO5126766 RO5126766 A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202) Completed USA | ITA | FRA | ESP | DEU 0
NCT04621188 Phase II Lorlatinib Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Recruiting FRA 0
NCT04622007 Phase II Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART) Active, not recruiting USA | AUS 1
NCT04623775 Phase II Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 10
NCT04625647 Phase II Sotorasib Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Recruiting USA 1
NCT04625699 Phase II Durvalumab + Tremelimumab Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment Withdrawn 0
NCT04634110 Phase II Brigatinib Brigatinib Before Brain Irradiation Trial (B3i Trial) Terminated USA 0
NCT04638582 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) Recruiting CAN 0
NCT04639245 Phase Ib/II MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer Terminated USA 0
NCT04642469 Phase III Durvalumab Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2) Completed USA | ITA | FRA | ESP | CAN | BEL | AUS 18
NCT04644237 Phase II Trastuzumab deruxtecan Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02) Active, not recruiting USA | ITA | FRA | ESP | CAN | AUS 4
NCT04648033 Phase I Atovaquone Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC (ARCADIAN) Completed GBR 0
NCT04655976 Phase II Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 15
NCT04656652 Phase III Docetaxel Datopotamab deruxtecan Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04667234 Expanded access Sotorasib Expanded Access of Sotorasib No longer available USA 5
NCT04676477 Phase I Patritumab deruxtecan Osimertinib + Patritumab deruxtecan HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer Recruiting USA 3
NCT04678908 Phase I HB0025 A Study of Injection HB0025 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04681131 Phase II Mecbotamab Vedotin Mecbotamab Vedotin + unspecified PD-1 antibody CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC Recruiting USA | ITA | ESP | DEU 4
NCT04683250 Phase Ib/II Vepafestinib Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET)) Recruiting USA 1
NCT04683939 Phase Ib/II BNT141 BNT141 + Gemcitabine + Nab-paclitaxel Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors Terminated USA | CAN 0
NCT04685135 Phase III Docetaxel Adagrasib Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 14
NCT04699123 Phase II NC318 + Pembrolizumab NC318 The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer Recruiting USA 0
NCT04701476 Phase II Pembrolizumab + Tirapazamine TATE and Pembrolizumab (MK3475) in mCRC and NSCLC Recruiting USA 1
NCT04716946 Phase II Durvalumab Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04721015 Phase I ABBV-637 + Docetaxel ABBV-637 + Osimertinib ABBV-637 Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors Active, not recruiting USA | FRA | ESP | AUS 4
NCT04725188 Phase II Docetaxel Docetaxel + MK-7684A MK-7684A Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 12
NCT04725331 Phase Ib/II BT-001 BT-001 + Pembrolizumab A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Recruiting FRA | BEL 0
NCT04731467 Phase Ib/II CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Active, not recruiting USA | ESP 1
NCT04735068 Phase II Binimetinib + Hydroxychloroquine Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT04736173 Phase III Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10) Active, not recruiting USA | FRA 16
NCT04738487 Phase III Pembrolizumab MK-7684A Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) Recruiting USA | CAN 21
NCT04739358 Phase Ib/II Tepotinib CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC Terminated USA 0
NCT04743505 Phase Ib/II Osimertinib + Vebreltinib Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT04746924 Phase III Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer Recruiting USA | FRA | DEU 6
NCT04748419 Phase Ib/II Durvalumab Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab Recruiting USA 0
NCT04752215 Phase I BI 765049 + Ezabenlimab BI 765049 A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker Recruiting USA | CAN 0
NCT04752826 Phase Ib/II BI-1808 + Pembrolizumab BI-1808 BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) Recruiting GBR 3
NCT04762199 Phase I MRX-2843 + Osimertinib MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Recruiting USA 0
NCT04765709 Phase II Cisplatin + Dulanermin + Vinorelbine Carboplatin + Durvalumab + Vinorelbine Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (BRIDGE) Active, not recruiting ITA | FRA | ESP 0
NCT04772989 Phase I AB308 + Zimberelimab A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) Active, not recruiting USA | ESP 1
NCT04776447 Phase II Atezolizumab + Carboplatin + Paclitaxel Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO) Recruiting ESP 0
NCT04777994 Phase I ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors Recruiting USA | FRA | ESP 3
NCT04780217 Phase Ib/II T3011 Pembrolizumab + T3011 A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT04780568 Phase I BC2059 + Osimertinib Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer Recruiting USA 0
NCT04786093 Phase II Durvalumab Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC Recruiting USA 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04789668 Phase Ib/II Bintrafusp alfa + Pimasertib Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Completed USA 0
NCT04791839 Phase II AB154 + Etrumadenant + Zimberelimab Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer Recruiting USA 0
NCT04793815 FDA approved Pembrolizumab Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) Completed CAN 0
NCT04795713 Phase I MT-6402 Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 Recruiting USA 0
NCT04800822 Phase I PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 PF-07284892 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04808362 Phase Ib/II OMO-103 Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) Active, not recruiting ESP 0
NCT04811001 Phase II Dacomitinib Osimertinib Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND) Recruiting ITA 0
NCT04816214 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Capmatinib + Osimertinib Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E) Terminated 3
NCT04819100 Phase III Selpercatinib A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 22
NCT04819373 Phase II BDB001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Completed USA 0
NCT04822298 Phase I AMG 160 Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer Terminated USA | AUT | AUS 0
NCT04827576 Phase II Docetaxel + Hu5F9-G4 Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) Active, not recruiting USA | GBR | FRA | ESP 1
NCT04830202 Expanded access Telisotuzumab vedotin Expanded Access to Telisotuzumab Vedotin Available USA | DEU | AUS 2
NCT04832854 Phase II Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer Active, not recruiting USA | ESP | AUS 2
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies Recruiting CAN 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Completed USA 0
NCT04837716 Phase I Bevacizumab + Carboplatin + Ensartinib + Pemetrexed Disodium Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04844073 Phase Ib/II MVC-101 A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer Recruiting USA | AUS 1
NCT04849273 Phase Ib/II TPX-0131 A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC Terminated USA | AUS 1
NCT04856176 Phase II Carboplatin + Paclitaxel + Pembrolizumab + Sargramostim Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sargramostim A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy Recruiting USA 0
NCT04862780 Phase Ib/II BLU-945 BLU-945 + Osimertinib (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Active, not recruiting USA | GBR | FRA | ESP | CAN 5
NCT04863248 Phase II Docetaxel + Trilaciclib Docetaxel Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) Terminated USA 0
NCT04866017 Phase III Durvalumab BGBA1217 + Tislelizumab Tislelizumab A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Terminated USA | AUS 2
NCT04868877 Phase Ib/II MCLA-129 A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | BEL 3
NCT04870112 Phase Ib/II Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) Terminated USA | ESP 2
NCT04875585 Phase II Lenvatinib + Pembrolizumab Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC (INNWOP1) Recruiting AUT 0
NCT04879849 Phase I Pembrolizumab + TAK-676 A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Active, not recruiting USA 0
NCT04880863 Phase II Docetaxel + Naptumomab estafenatox + Obinutuzumab Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1) Completed USA 0
NCT04884282 Phase II Docetaxel + OSE 2101 Docetaxel Nivolumab + OSE 2101 Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED) Recruiting ITA | FRA | ESP 0
NCT04892017 Phase Ib/II DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Recruiting USA 0
NCT04892472 Phase II Pembrolizumab EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36) Recruiting USA 0
NCT04892953 Phase II Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Recruiting USA 0
NCT04895579 Phase I Copanlisib + Durvalumab Lung Cancer With Copanlisib and Durvalumab (LCD) Active, not recruiting USA 0
NCT04898543 Phase I ALT-803 + m-ceNK cells QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04902040 Phase Ib/II Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Recruiting USA 0
NCT04903873 Phase Ib/II EU101 A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04905316 Phase II Canakinumab + Durvalumab A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (CHORUS) Active, not recruiting USA 0
NCT04908956 Phase II Osimertinib Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO) Active, not recruiting ITA | ESP 6
NCT04914897 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 Pembrolizumab + THOR-707 Nab-paclitaxel + Pembrolizumab + THOR-707 Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) Active, not recruiting USA | ITA | FRA | ESP | AUS 6
NCT04916236 Phase I LY3214996 + RMC-4630 Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) Recruiting 1
NCT04919369 Phase I Atezolizumab + Tretinoin All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Recruiting USA 0
NCT04919811 Phase II Taletrectinib Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) Recruiting USA | ITA | FRA | ESP | CAN 4
NCT04921358 Phase III Docetaxel Sitravatinib + Tislelizumab Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Terminated AUS 1
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Recruiting USA | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04926831 Phase II Capmatinib Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N) Active, not recruiting USA 0
NCT04928846 Phase III Telisotuzumab vedotin Docetaxel A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 21
NCT04929041 Phase II Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Recruiting USA 0
NCT04933695 Phase II Sotorasib A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (CodeBreaK201) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 4
NCT04933903 Phase II Ipilimumab + Nivolumab BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab Recruiting USA 0
NCT04939701 Phase Ib/II ASP0739 + Pembrolizumab ASP0739 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants Completed USA 0
NCT04940299 Phase II Ipilimumab + Nivolumab + Tocilizumab Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Active, not recruiting USA 0
NCT04940325 Phase II Datopotamab deruxtecan Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01) Recruiting FRA 0
NCT04940637 Phase II Dostarlimab-gxly + Niraparib UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001) Recruiting ITA 0
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Recruiting USA | CAN | BEL 4
NCT04944173 Phase II Durvalumab A Study of Durvalumab and Stereotactic Radiotherapy for Stage I Non-Small Cell Lung Cancer (SCION) Recruiting CAN 0
NCT04957290 Phase Ib/II NOX66 A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Terminated USA 0
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Recruiting USA | ITA | ESP | BEL 2
NCT04959981 Phase Ib/II ERAS-007 + Osimertinib ERAS-601 + Sotorasib ERAS-007 + Sotorasib A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2) Completed USA 0
NCT04964960 Phase II Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab Pembro+Chemo in Brain Mets Active, not recruiting USA 0
NCT04965090 Phase II Amivantamab-vmjw + Lazertinib A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT04965818 Phase Ib/II Binimetinib + Futibatinib Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Terminated USA 0
NCT04966663 Phase II Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Gemcitabine + Nivolumab Using ctDNA to Determine Therapies for Lung Cancer (ctDNA Lung RCT) Recruiting CAN 0
NCT04966676 Phase II Ipilimumab + Nivolumab Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS) Recruiting CAN 0
NCT04969315 Phase Ib/II TT-10 TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors Recruiting USA 0
NCT04969835 Phase I AVA6000 A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Recruiting USA | GBR 0
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Active, not recruiting USA | GBR | ESP | BEL 0
NCT04975256 Phase I Adagrasib + BI 1701963 Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) Completed USA 0
NCT04982224 Phase Ib/II REGN5093-M114 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Recruiting USA 0
NCT04982926 Phase I TAS2940 A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer Recruiting USA | FRA 0
NCT04984811 Phase II Atezolizumab + NT-I7 NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Active, not recruiting USA 0
NCT04989283 Phase II Carboplatin Atezolizumab + Cisplatin Atezolizumab + Paclitaxel Atezolizumab + Etoposide Cisplatin Etoposide Paclitaxel Atezolizumab + Carboplatin Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer Withdrawn USA 0
NCT04999202 Phase I BAY2416964 + Pembrolizumab BAY2416964 A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults Active, not recruiting USA | ITA | GBR 1
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05001347 Phase II Uliledlimab A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors Completed USA 0
NCT05005273 Phase II Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer Completed USA | ITA | FRA | ESP | DEU | BEL | AUS 5
NCT05005403 Phase I ABBV-514 + Budigalimab ABBV-514 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab Recruiting USA 3
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 1
NCT05007769 Phase II ALT-803 + Atezolizumab + Ramucirumab Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN) Withdrawn 0
NCT05012254 Phase II Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain) Recruiting ESP 0
NCT05013450 Phase Ib/II Dupilumab + unspecified PD-L1 antibody Dupilumab + unspecified PD-1 antibody Dupilumab_Metastatic NSCLC Recruiting USA 0
NCT05014815 Phase II BGBA1217 + Tislelizumab Tislelizumab Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Active, not recruiting USA | FRA | ESP | AUT | AUS 2
NCT05029882 Phase I ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Recruiting USA | FRA | ESP | AUS 6
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05041972 Phase II ARX-788 ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) Withdrawn USA 0
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Recruiting USA | GBR 0
NCT05054725 Phase II RMC-4630 + Sotorasib Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 2
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05061017 Phase II Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Active, not recruiting USA 0
NCT05061537 Phase I PF-06801591 + PF-07263689 PF-07263689 Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Terminated USA 0
NCT05061550 Phase II Durvalumab + Monalizumab Durvalumab + Oleclumab Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) Recruiting USA | ITA | FRA | ESP | CAN | BEL 6
NCT05062980 Phase Ib/II Pembrolizumab + Quaratusugene Ozeplasmid Docetaxel + Ramucirumab Reqorsa (Quaratusugene Ozeplasmid) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (Acclaim-2) Recruiting USA 0
NCT05064280 Phase II Lenvatinib Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT05067283 Phase I MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Advanced Solid Tumors (MK-1084-001) Recruiting USA | ESP | CAN | AUS 11
NCT05068024 Phase Ib/II FWD1509 MsOH A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509) Recruiting USA 0
NCT05068102 Phase I BI 770371 + Ezabenlimab Effi-DEM + Ezabenlimab A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab Recruiting 1
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05074810 Phase Ib/II RO5126766 + Sotorasib Defactinib + RO5126766 + Sotorasib Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP203) Recruiting USA | GBR | BEL 1
NCT05075564 Phase I ES002023 A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT05076760 Phase I MEM-288 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05077709 Phase II IO102-IO103 + Pembrolizumab IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Recruiting USA | GBR | ESP 0
NCT05082610 Phase I HMBD-002 HMBD-002 + Pembrolizumab A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab Recruiting USA 0
NCT05083481 Phase Ib/II ASP1570 A Study of ASP1570 in Adults With Locally Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT05084859 Phase I Abiraterone + Prednisone + SM08502 Fluorouracil + Irinotecan + Leucovorin + Panitumumab + SM08502 Docetaxel + SM08502 A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors Active, not recruiting USA | AUS 0
NCT05085028 Phase III Pembrolizumab A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (REFINE-Lung) Recruiting GBR 0
NCT05089734 Phase III Docetaxel Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy (EVOKE-01) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT05089916 Phase II Osimertinib Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) Recruiting DEU 0
NCT05091528 Phase Ib/II SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers Terminated USA 0
NCT05094336 Phase Ib/II AMG193 AMG193 + Docetaxel AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP) Recruiting USA | GBR | FRA | DEU | CAN | BEL | AUT | AUS 5
NCT05094804 Phase Ib/II Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor Recruiting USA 0
NCT05096663 Phase II Dexamethasone + Docetaxel + Gemcitabine + Pemetrexed Disodium + Ramucirumab ALT-803 + Pembrolizumab Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Active, not recruiting USA 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated FRA 1
NCT05099172 Phase I BAY2927088 First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) Recruiting USA | ITA | FRA | ESP | BEL 11
NCT05099549 Phase Ib/II AFM24 + SNK01 Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers Terminated USA 0
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT05102214 Phase Ib/II HLX301 HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05104515 Phase I OVM-200 First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine Recruiting GBR 0
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05109442 Phase Ib/II AFM24 + Atezolizumab Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers Recruiting USA | GBR | ESP 2
NCT05116891 Phase Ib/II Cisplatin + Gemcitabine + Nidanilimab Docetaxel + Nidanilimab Fluorouracil + Leucovorin + Nidanilimab + Oxaliplatin A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Completed FRA | ESP 0
NCT05117242 Phase II GEN1046 + Pembrolizumab GEN1046 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Recruiting USA | ITA | GBR | FRA | ESP | DEU 3
NCT05118789 Phase Ib/II NUV-520 A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Recruiting USA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT05118841 Phase I ZX-4081 Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05119933 Phase Ib/II YL-15293 A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation Unknown status USA 0
NCT05120960 Phase I Tepotinib Osimertinib + Tepotinib A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors Recruiting USA 0
NCT05121948 Phase I HC-7366 A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Terminated USA 0
NCT05128630 Phase II Durvalumab Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS) Recruiting ITA 0
NCT05132075 Phase III JDQ443 Docetaxel Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) Recruiting USA | ITA | GBR | ESP | CAN | AUS 31
NCT05136846 Phase I Carboplatin + Durvalumab + Paclitaxel + Papaverine Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer Recruiting USA 0
NCT05141357 Phase II Chidamide + Pembrolizumab A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (HBI-8000) Terminated USA 0
NCT05142189 Phase I BNT116 + Cemiplimab BNT116 + Docetaxel BNT116 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1) Recruiting USA | ESP | DEU 3
NCT05144529 Phase II Ipilimumab + Nivolumab Evolocumab + Ipilimumab + Nivolumab A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101) Recruiting USA 0
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05144997 FDA approved Lorlatinib Lorlatinib Continuation Study Recruiting USA | FRA | ESP 3
NCT05153408 Phase Ib/II BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Terminated USA 0
NCT05159518 Phase I PRT2527 A Study of PRT2527 in Participants With Advanced Solid Tumors Completed USA 0
NCT05163041 Phase Ib/II BT7480 BT7480 + Nivolumab Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression Recruiting USA | GBR 0
NCT05166616 Phase I Minnelide + Osimertinib Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer Recruiting USA 0
NCT05168566 Phase II Sutetinib maleate Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Recruiting USA 0
NCT05171062 Phase I FP-1305 + Pembrolizumab Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer Withdrawn USA 0
NCT05171777 Phase II Atezolizumab A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | ESP | CAN 8
NCT05180422 Phase Ib/II Bevacizumab-awwb + Sotorasib A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis Withdrawn USA 0
NCT05186974 Phase II Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Pembrolizumab + Sacituzumab govitecan-hziy Cisplatin + Pembrolizumab + Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan-hziy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations (EVOKE-02) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT05200481 Phase II Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) Recruiting FRA 0
NCT05200559 Phase Ib/II E7777 + Pembrolizumab T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Recruiting USA 0
NCT05208762 Phase I SGN-PDL1V A Study of SGN-PDL1V in Advanced Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 1
NCT05208944 Phase II Cemiplimab + THIO A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab in Subjects With Advanced NSCLC Recruiting AUS 3
NCT05211895 Phase III Durvalumab AB154 + Durvalumab A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 18
NCT05212922 Phase II Toripalimab-tpzi + YH001 A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001) Withdrawn AUT | AUS 3
NCT05215340 Phase III Pembrolizumab Datopotamab deruxtecan + Pembrolizumab Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT05221840 Phase III Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT05226598 Phase III Carboplatin + MK-7684A + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + MK-7684A + Pemetrexed Disodium Carboplatin + MK-7684A + Nab-paclitaxel Carboplatin + MK-7684A + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Active, not recruiting USA | GBR | FRA | ESP | DEU | AUT 13
NCT05228015 Phase I IK-930 Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT05229614 Phase II Pembrolizumab Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) Recruiting ITA | DEU 0
NCT05229900 Phase I SGN-ALPV A Study of SGN-ALPV in Advanced Solid Tumors Terminated USA | GBR | ESP | CAN 1
NCT05233436 Phase I PF-07265028 PF-06801591 + PF-07265028 PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors Terminated USA 1
NCT05234307 Phase I Nivolumab + PBF-1129 PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Recruiting USA 0
NCT05238883 Phase I HFB200301 HFB200301 + Tislelizumab A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05241873 Phase Ib/II BLU-451 (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Active, not recruiting USA | CAN 3
NCT05253807 Phase II Pemigatinib Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210) Completed USA | ITA | FRA | ESP | DEU 0
NCT05255302 Phase II Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL) Recruiting FRA 0
NCT05256290 Phase I BDTX-1535 BDTX-1535 + Temozolomide Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Recruiting USA 1
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | BEL 4
NCT05259319 Phase I Atezolizumab + Tiragolumab Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) Recruiting FRA 0
NCT05259696 Phase Ib/II E-602 E-602 + Pembrolizumab Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) Recruiting USA 0
NCT05261399 Phase III Osimertinib + Savolitinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 21
NCT05262530 Phase Ib/II BNT142 Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors Recruiting USA | GBR | ESP 1
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05265650 Phase Ib/II BO-112 + Nivolumab Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (Noelia) Recruiting ESP 0
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05274451 Phase I LYL797 A Study to Investigate LYL797 in Adults With Solid Tumors Recruiting USA 0
NCT05275374 Phase Ib/II BI 882370 + Trametinib BI 882370 XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) Not yet recruiting 0
NCT05275478 Phase Ib/II TNG908 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors Recruiting USA | FRA 0
NCT05275868 Phase I MGY825 Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer Recruiting USA | ESP | DEU 3
NCT05277051 Phase I GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CAN | AUS 3
NCT05281406 Phase II Carboplatin + Osimertinib + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) Recruiting DEU 0
NCT05298176 Phase II Afatinib Afatinib + Carboplatin + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION) Recruiting 1
NCT05298423 Phase III Cisplatin + MK-7684A + Pemetrexed Disodium Cisplatin + Durvalumab + Paclitaxel Carboplatin + MK-7684A + Paclitaxel Cisplatin + Etoposide + MK-7684A Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Etoposide Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) Recruiting USA | ITA | ESP | DEU | AUS 16
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Recruiting USA | ESP | BEL 3
NCT05306444 Phase I HBM7008 HBM7008 -Study on Subjects With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05313009 Phase Ib/II Sotorasib + TH-4000 Tarlox and Sotorasib in Patients With KRAS G12C Mutations Terminated USA 0
NCT05317078 Phase I AMG 794 A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications Active, not recruiting USA | AUS 1
NCT05317858 Phase III Pembrolizumab Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets Recruiting USA | CAN 1
NCT05332574 Phase Ib/II GB263T A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor Recruiting AUS 0
NCT05340309 Phase II Atezolizumab + rHuPH20 Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer Recruiting USA 0
NCT05358249 Phase Ib/II JDQ443 + Ribociclib JDQ443 + Trametinib Cetuximab + JDQ443 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) Recruiting USA | ITA | FRA | ESP | DEU | BEL 2
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05358548 Phase II Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab ATATcH Alternating Treatment Plans for Advanced Cancer Recruiting USA 0
NCT05358691 Phase I Durvalumab + E7046 A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants Not yet recruiting USA 0
NCT05361174 Phase Ib/II IOV-4001 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer Recruiting USA 0
NCT05364073 Phase I Furmonertinib Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 4
NCT05364645 Phase II Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Recruiting USA 0
NCT05374538 Phase I VIC-1911 Sotorasib + VIC-1911 VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer Terminated USA 0
NCT05375084 Phase I BBP-398 + Nivolumab SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation Recruiting USA 0
NCT05375994 Phase Ib/II Adagrasib + RO5126766 Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204) Recruiting USA 0
NCT05378763 Phase III Poziotinib Docetaxel A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE) Suspended USA 0
NCT05383001 Phase II Cisplatin + Vinorelbine Carboplatin + Vinorelbine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Nab-paclitaxel Durvalumab + Tremelimumab Carboplatin + Nab-paclitaxel Cisplatin + Gemcitabine Carboplatin + Gemcitabine Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) Withdrawn DEU 0
NCT05384626 Phase Ib/II NUV-655 A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Recruiting USA | GBR | FRA | ESP | CAN | AUS 0
NCT05388435 Phase Ib/II SKL27969 Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients Active, not recruiting USA 0
NCT05388669 Phase III Amivantamab-vmjw + Lazertinib A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 12
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT05393635 Phase I ITIL-168 + Pembrolizumab ITIL-168 in Advanced Solid Tumors (DELTA-2) Withdrawn 0
NCT05394831 Phase Ib/II JIN-A02 A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC Recruiting USA 2
NCT05397171 Phase Ib/II AZD8853 A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours Terminated USA | CAN 0
NCT05398094 Phase II Sotorasib Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung) Recruiting ESP 0
NCT05401786 Phase II Cemiplimab Ipilimumab Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO) Recruiting 1
NCT05417321 Phase Ib/II HB0036 A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT05430009 Phase I Pembrolizumab Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer Recruiting USA 0
NCT05435846 Phase I Capmatinib + Trametinib Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Recruiting USA 0
NCT05438329 Phase Ib/II DB-1305 First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors Recruiting USA 2
NCT05443971 Phase II Durvalumab Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen Recruiting USA 0
NCT05445843 Phase II JDQ443 Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression >= 1% and an STK11 Co-mutation. Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT 13
NCT05450562 Phase Ib/II Atezolizumab + SAR444200 SAR444200 Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors Recruiting USA | CAN 3
NCT05450692 Phase III Docetaxel Ceralasertib + Durvalumab A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT05462873 Phase I QEQ278 A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | BEL 3
NCT05467748 Phase Ib/II Tazemetostat EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer Not yet recruiting USA 0
NCT05472623 Phase II Adagrasib + Nivolumab Adagrasib Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab (Neo-Kan) Recruiting USA 0
NCT05483491 Phase I Aldesleukin + KK-LC-1 TCR-T cells KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Recruiting USA 0
NCT05487235 Phase I Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | ESP | CAN | AUS 5
NCT05488314 Phase II Amivantamab-vmjw + Capmatinib A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 6
NCT05493501 Phase III Aumolertinib + Cisplatin + Pemetrexed Disodium Aumolertinib + Carboplatin + Pemetrexed Disodium Aumolertinib + Carboplatin + Paclitaxel Aumolertinib + Cisplatin + Paclitaxel Aumolertinib + Cisplatin + Nab-paclitaxel Aumolertinib + Carboplatin + Nab-paclitaxel Aumolertinib + Cisplatin + Gemcitabine Aumolertinib Aumolertinib + Carboplatin + Gemcitabine Osimertinib Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Terminated USA 0
NCT05493566 Phase I Aldesleukin + Pembrolizumab Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Recruiting USA 0
NCT05496595 Phase I DCBY02 DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT05498389 Phase Ib/II EMB-01 + Osimertinib EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer Not yet recruiting USA 1
NCT05498428 Phase II Amivantamab-vmjw Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2) Recruiting USA | ITA | GBR | FRA | ESP | DEU 6
NCT05500092 Phase II Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (CA209-6K6) Recruiting USA 0
NCT05500508 Phase Ib/II AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With IV DFMO Recruiting USA | AUS 0
NCT05501665 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Pembrolizumab Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer Recruiting USA 0
NCT05502237 Phase III AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 13
NCT05514496 Phase I NX-019 A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer Recruiting USA 2
NCT05519293 Phase Ib/II H002 Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation Recruiting USA 0
NCT05525338 FDA approved Alectinib Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) Recruiting FRA 1
NCT05526755 Phase II Osimertinib A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET) Recruiting USA | ITA | GBR | ESP 7
NCT05533697 Phase Ib/II mRNA-4359 + Pembrolizumab mRNA-4359 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | AUS 0
NCT05537740 Phase I BAY 3375968 + Pembrolizumab BAY 3375968 A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors Recruiting USA | GBR | CAN | BEL 1
NCT05538572 Phase I PRT3645 A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors Active, not recruiting USA 1
NCT05541822 Phase II ABN401 To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation Recruiting USA 2
NCT05544929 Phase I KFA115 + Tislelizumab KFA115 A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers Recruiting USA | CAN 4
NCT05546268 Phase Ib/II MRT-2359 Study of Oral MRT-2359 in Selected Cancer Patients Recruiting USA | CAN 0
NCT05547321 Phase I OMTX705 + Pembrolizumab OMTX705 Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. Recruiting USA | ESP 0
NCT05548634 Phase I TAVO412 A Study of TAVO412 in Patients With Cancer (TAVO412) Recruiting USA 0
NCT05555732 Phase III Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Recruiting USA | ESP | CAN | AUS 9
NCT05565378 Phase II Dostarlimab-gxly Dostarlimab-gxly + EOS-448 Pembrolizumab A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL 15
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05566223 Phase Ib/II Aldesleukin + CISH-inactivated autologous TILs + Cyclophosphamide + Fludarabine Pembrolizumab Phase 1/2 Study of CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2) Not yet recruiting USA 0
NCT05568212 Phase II Durvalumab Durvalumab + Olaparib Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab Recruiting ITA 0
NCT05570825 Phase II Pembrolizumab + SX-682 SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer Recruiting USA 0
NCT05571839 Phase I SGN-BB228 A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors Recruiting USA | GBR | FRA | DEU | CAN 1
NCT05573035 Phase I LYL845 A Study to Investigate LYL845 in Adults With Solid Tumors Recruiting USA 0
NCT05576077 Phase I Pembrolizumab + TBio-4101 A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) Recruiting USA | CAN 0
NCT05578092 Phase Ib/II Adagrasib + MRTX0902 MRTX0902 A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway Recruiting USA 1
NCT05579366 Phase Ib/II PRO1184 PRO1184 for Advanced Solid Tumors (PRO1184-001) Recruiting USA 1
NCT05580770 Phase Ib/II BGB3245 + PD-0325901 Mirdametinib + BGB-3245 in Advanced Solid Tumors Recruiting USA | AUS 0
NCT05583188 FDA approved Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Carboplatin Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Cisplatin Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Pemetrexed Disodium Vinorelbine Gemcitabine Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Neoadjuvant Aliya PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR) Active, not recruiting USA 0
NCT05584670 Phase Ib/II SAR445877 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors Recruiting USA | ESP 2
NCT05585034 Phase I Pembrolizumab + XmAb808 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT05585320 Phase Ib/II IMM-1-104 A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05588609 Phase II Enzalutamide + Zenocutuzumab Afatinib + Zenocutuzumab Abiraterone + Zenocutuzumab Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers Recruiting USA 0
NCT05589818 Phase II Pembrolizumab Pembrolizumab for Advanced NSCLC and PS 2-3 Recruiting USA 0
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | CAN 0
NCT05597800 Phase II Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR) Not yet recruiting ITA 0
NCT05597839 Phase Ib/II DF9001 DF9001 + Nivolumab Study of DF9001 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05609578 Phase II Adagrasib + Pembrolizumab Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Recruiting USA | ITA | FRA | ESP 3
NCT05609968 Phase III Pembrolizumab Pembrolizumab + Sacituzumab govitecan-hziy Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-3475-D46) Recruiting USA | ITA | GBR | DEU | CAN | AUS 18
NCT05613413 Phase II Cabozantinib + Pembrolizumab A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127) Recruiting USA 0
NCT05614102 Phase I BAY2965501 A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | BEL 3
NCT05617313 Phase II GT103 + Pembrolizumab Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer Suspended USA 0
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05620342 Phase I iC9.GD2.CAR.IL-15 T-cells Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer Recruiting USA 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05624996 Phase III Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer Recruiting USA 0
NCT05625412 Phase I CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | CAN | AUS 3
NCT05631249 Phase II Sotorasib Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CODEBREAK-IGR) Recruiting FRA 0
NCT05631574 Phase I BMF-219 Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Recruiting USA 1
NCT05632809 Phase II Durvalumab + NKTR-255 REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) Recruiting USA 0
NCT05633602 Phase III Pembrolizumab + Ramucirumab Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study Recruiting USA 0
NCT05633667 Phase II Etrumadenant + Sacituzumab govitecan-hziy + Zimberelimab Carboplatin + Paclitaxel + Zimberelimab Carboplatin + Nab-paclitaxel + Zimberelimab Docetaxel Etrumadenant + Zimberelimab Cisplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pemetrexed Disodium + Zimberelimab AB154 + Sacituzumab govitecan-hziy + Zimberelimab AB154 + Etrumadenant + Zimberelimab Sacituzumab govitecan-hziy Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Recruiting USA 4
NCT05635708 Phase II Nab-paclitaxel Cisplatin BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Recruiting USA | ITA | ESP | CAN | AUS 9
NCT05642195 Phase Ib/II ALT-803 + H1299 cell lysate vaccine + Montanide ISA 51 H1299 cell lysate vaccine + Montanide ISA 51 Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Recruiting USA 0
NCT05642572 Phase II Capmatinib + Osimertinib Capmatinib + Osimertinib + Ramucirumab Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) Recruiting USA 0
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05647122 Phase I AZD9592 AZD9592 + Osimertinib First in Human Study of AZD9592 in Solid Tumors (EGRET) Recruiting USA | ITA | FRA | ESP | CAN | AUS 5
NCT05650203 Phase I JS006 + JS009 + Toripalimab-tpzi JS009 A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies Withdrawn 0
NCT05650879 Phase I ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) Recruiting USA | ITA | FRA | ESP | AUS 2
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05652868 Phase I MYTX-011 Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Recruiting USA | AUS 1
NCT05653752 Phase I YL202 A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer Recruiting USA 1
NCT05663866 Phase II Amivantamab-vmjw + Dexamethasone + Lazertinib Amivantamab-vmjw + Lazertinib + Montelukast Amivantamab-vmjw + Lazertinib + Methotrexate Premedication to Mitigate Amivantamab Infusion Related Reactions Recruiting USA | FRA | ESP 2
NCT05668585 Phase Ib/II CFT1946 + Trametinib CFT1946 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors Recruiting USA | FRA | ESP 0
NCT05669846 Phase II Fecal microbiota + Pembrolizumab Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC Not yet recruiting USA 0
NCT05671510 Phase III ONC-392 Docetaxel ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT05673187 Phase II Adagrasib Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT) Recruiting ITA | GBR | FRA | ESP | BEL 1
NCT05676749 Phase I Aldesleukin + C-TIL051 + Pembrolizumab C-TIL051 in Non-Small Cell Lung Cancer Recruiting USA 0
NCT05676931 Phase II AB680 + Zimberelimab AB154 + Zimberelimab AB154 + AB680 + Zimberelimab AB680 + Docetaxel + Zimberelimab AB154 + Docetaxel + Zimberelimab Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung) Recruiting USA | AUS 1
NCT05681780 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC Recruiting USA 0
NCT05683418 Phase I TOS-358 A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors Recruiting USA 0
NCT05684276 Phase II Carboplatin + Nivolumab + Paclitaxel DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors (DUMAS) Recruiting ESP 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05687266 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 16
NCT05688280 Phase Ib/II IP-001 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1) Recruiting USA | GBR | FRA | DEU 1
NCT05691829 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC (IRRADIATE-Lung) Recruiting USA 0
NCT05696782 Phase II Durvalumab Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer Recruiting USA 0
NCT05700721 Phase II Dostarlimab-gxly + Niraparib Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) Recruiting USA 0
NCT05704985 Phase I DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Recruiting USA 0
NCT05709821 Phase Ib/II Pembrolizumab IMM60 IMM60 + Pembrolizumab IMM60 and Pembrolizumab in Melanoma and NSCLC Active, not recruiting USA | GBR | ESP 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05714891 Phase II JDQ443 Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer Recruiting CAN 0
NCT05715229 Phase II Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT) Recruiting USA 0
NCT05718297 Phase II Brigatinib Durvalumab Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE) Recruiting ITA | GBR | FRA | ESP 1
NCT05718557 Phase I PYX-106 Study of PYX-106 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05719558 Phase I ASP1002 A Study of ASP1002 in Adults for Treatment of Solid Tumors Recruiting USA 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05722015 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + MK-3475A + Nab-paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Cisplatin + MK-3475A + Pemetrexed Disodium Carboplatin + MK-3475A + Paclitaxel A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) Active, not recruiting USA | FRA | ESP 13
NCT05731271 Phase Ib/II TST003 A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Recruiting USA 0
NCT05736731 Phase Ib/II A2B530 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) Recruiting USA 0
NCT05742607 Phase II Cisplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Paclitaxel IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) Recruiting USA | FRA 3
NCT05756153 Phase Ib/II Cetuximab + IBI351 A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation Recruiting ITA | ESP 1
NCT05757492 Phase Ib/II CHS-006 + Toripalimab-tpzi Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT05757843 Phase II Durvalumab Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab Recruiting USA 0
NCT05765734 Phase Ib/II TAS3351 A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351) Recruiting USA | ITA | GBR | FRA | ESP | DEU 3
NCT05769075 Phase I TY-2136b A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations Recruiting USA 0
NCT05775289 Phase II Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT05777603 Phase I Aztreonam + Pembrolizumab + Vancomycin Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer Recruiting USA 0
NCT05781308 Phase II Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE) Recruiting FRA 0
NCT05782361 Phase I Pembrolizumab + Tepotinib POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (POTENT) Recruiting GBR 0
NCT05783622 Phase I JANX008 Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies Recruiting USA 0
NCT05785208 FDA approved Osimertinib Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2) Recruiting ITA 0
NCT05785741 Phase Ib/II DB-1310 A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT05785754 Phase I DCSZ11 DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 0
NCT05785767 Phase II Cemiplimab Cemiplimab + Fianlimab A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Recruiting USA | AUS 2
NCT05786924 Phase I BDTX-4933 A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Recruiting USA 0
NCT05788926 Phase I TG6050 A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) Recruiting FRA 0
NCT05789069 Phase I HFB200603 HFB200603 + Tislelizumab A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ITA | ESP 0
NCT05789082 Phase Ib/II Divarasib + Pembrolizumab A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170) Recruiting USA | ITA | GBR | ESP | CAN | BEL | AUS 11
NCT05798663 Phase II Atezolizumab Atezolizumab + Tiragolumab Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC Recruiting USA 0
NCT05800964 Phase I AMG 305 Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. Recruiting USA | FRA | ESP | DEU | AUS 1
NCT05801029 Phase II Amivantamab-vmjw + Osimertinib A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA) Recruiting CAN 6
NCT05807048 Phase II Daratumumab and hyaluronidase-fihj Daratumumab in STK11 Mutated NSCLC Recruiting USA 0
NCT05815173 Phase I Ladarixin + Sotorasib Ladarixin With Sotorasib in Advanced NSCLC Recruiting USA 0
NCT05815186 Phase II Ladarixin + Sotorasib Ladarixin With Sotorasib in Advanced NSCLC - Phase II Withdrawn USA 0
NCT05821777 Phase Ib/II LB101 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors Recruiting USA | FRA 0
NCT05825625 Phase II Atezolizumab + Tiragolumab NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing Recruiting DEU 0
NCT05826600 Phase I OMX-0407 A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically Recruiting ESP 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05840510 Phase Ib/II Adagrasib + Nab-rapamycin Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) Recruiting USA 0
NCT05840770 Phase II Cemiplimab Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer Not yet recruiting USA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05845671 Phase Ib/II Amivantamab-vmjw Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations Recruiting USA 0
NCT05846646 Phase II Pembrolizumab Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Recruiting USA 0
NCT05848739 Phase I ST316 A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Recruiting USA 0
NCT05848843 Phase I Adagrasib + Durvalumab A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations Withdrawn USA 0
NCT05853575 Phase II Adagrasib Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Recruiting USA | FRA 2
NCT05858164 Phase I BAY2862789 A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors Recruiting USA | AUS 2
NCT05859217 Phase II Atezolizumab + Cabozantinib A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1) Not yet recruiting USA 0
NCT05860296 Phase Ib/II Pembrolizumab + SLC-391 Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Recruiting USA | CAN 0
NCT05862324 Phase Ib/II TAC01-CLDN18.2 TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) Recruiting USA | CAN 0
NCT05865990 Phase II Patritumab deruxtecan HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) Recruiting ESP | AUT 0
NCT05875168 Phase Ib/II DS-3939a First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Recruiting USA 1
NCT05877599 Phase I NT-175 A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Recruiting USA 0
NCT05879822 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Recruiting 11
NCT05888831 Phase Ib/II BMS-986449 + Nivolumab BMS-986449 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | BEL 1
NCT05891171 Phase I AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) Recruiting USA 0
NCT05898763 Phase Ib/II Pembrolizumab + TEIPP24 TEIPP24 TEIPP Immunotherapy in Patients With NSCLC Recruiting 1
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05908734 Phase Ib/II Amivantamab-vmjw + Cetrelimab A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Recruiting USA 2
NCT05911308 Phase I Carboplatin + Durvalumab + Nab-paclitaxel + Pemetrexed Disodium + RGX-104 Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer Not yet recruiting USA 0
NCT05914116 Phase Ib/II DB-1311 A Study of DB-1311 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 0
NCT05919264 Phase Ib/II FOG-001 FOG-001 in Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05919537 Phase Ib/II Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Recruiting AUS 0
NCT05920135 Phase Ib/II BBT-207 First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI Recruiting USA 1
NCT05920356 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Sotorasib A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT05920408 Phase Ib/II EXS21546 Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours Terminated FRA | BEL 0
NCT05925530 Phase II Durvalumab Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 4
NCT05934539 Phase Ib/II ALG.APV-527 ALG.APV-527 First-in-human Study Recruiting USA 0
NCT05935774 Phase II Atezolizumab + Trabedersen OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer Withdrawn USA 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05948462 Phase II Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC) Withdrawn USA 0
NCT05948865 Phase I CPO301 A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Recruiting USA | CAN 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT05967689 Phase II Zipalertinib A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT05975073 Phase Ib/II AMG193 + IDE397 A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors Recruiting USA | AUS 0
NCT05983133 Phase I SGN-EGFRd2 A Study of SGN-EGFRd2 in Advanced Solid Tumors Recruiting USA 0
NCT05983432 Phase I BL-B01D1 Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05984277 Phase III Carboplatin + MEDI5752 + Pemetrexed Disodium Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT05985655 Phase Ib/II GTAEXS617 Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) Recruiting GBR | BEL 0
NCT05987644 Phase Ib/II Alectinib Delayed or Upfront Brain RAdiotherapy in Treatment naive Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE) Recruiting USA 0
NCT06003231 Phase II Disitamab vedotin A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting USA | CAN 0
NCT06007937 Phase Ib/II Lorlatinib + Ramucirumab A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer Recruiting USA 0
NCT06010329 Phase II Sutetinib maleate A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC Recruiting USA 0
NCT06014827 Phase II Osimertinib Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma Recruiting USA 0
NCT06015724 Phase II Daratumumab + Nivolumab + QS21 + TG01 Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX) Recruiting USA 0
NCT06024174 Phase Ib/II Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398 A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors Recruiting USA | ITA | FRA | ESP | BEL | AUS 2
NCT06026410 Phase I Cabozantinib + KO-2806 KO-2806 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) Recruiting USA 0
NCT06034860 Phase I MT-8421 + Nivolumab MT-8421 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Recruiting USA 0
NCT06036121 Phase I ADRX-0706 A Study of ADRX-0706 in Select Advanced Solid Tumors Recruiting USA 0
NCT06039384 Phase I Adagrasib + INCB099280 A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT06043817 Phase Ib/II STX-721 First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Recruiting USA 0
NCT06046495 Phase I PLB1004 A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06051695 Phase Ib/II A2B694 A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) Recruiting USA 0
NCT06052852 Phase Ib/II BDC-3042 + Pembrolizumab BDC-3042 Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies Recruiting USA 0
NCT06060613 Phase Ib/II OBX-115 Safety and Efficacy of OBX-115 in Advanced Solid Tumors Recruiting USA 0
NCT06064279 Phase Ib/II Poly ICLC Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC (HAITEN-ICI) Not yet recruiting USA 0
NCT06066424 Phase I Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) Recruiting USA 0
NCT06067776 Phase I Cetuximab + Osimertinib + Tucatinib Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer Not yet recruiting USA 0
NCT06068153 Phase II Lenvatinib + Sotorasib AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC (AMBER) Not yet recruiting ESP | DEU | AUT 1
NCT06069570 Phase I KB-GDT-01 Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC Recruiting USA 0
NCT06077760 Phase III mRNA-4157 + Pembrolizumab Pembrolizumab A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) Recruiting USA | AUS 3
NCT06083454 Phase I Durvalumab Durvalumab + Vitamin C Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT06083857 Phase Ib/II Amivantamab-vmjw + Tepotinib PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Not yet recruiting USA 0
NCT06084689 Phase II BI 907828 + Ezabenlimab Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) Not yet recruiting FRA 0
NCT06088771 Phase Ib/II Cemiplimab + Dupilumab Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC Recruiting USA 0
NCT06094296 Phase II Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Recruiting USA | ITA | FRA | ESP 4
NCT06096844 Phase III Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Recruiting USA 0
NCT06099639 Expanded access Patritumab deruxtecan Medical Access Program for Patritumab Deruxtecan Available USA 0
NCT06099782 Phase II MK-3475A Pembrolizumab A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) Recruiting USA | FRA | AUS 4
NCT06105021 Phase Ib/II AFNT-211 Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor Recruiting USA 0
NCT06108050 Phase I JZP898 + Pembrolizumab JZP898 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06108479 Phase I DF6215 Study of DF6215 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06116786 Phase I Cetrelimab + JNJ-86974680 A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer Recruiting USA 1
NCT06119581 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 19
NCT06120075 Phase I AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) Recruiting USA 0
NCT06120283 Phase I BGB-43395 BGB-43395 + Letrozole BGB-43395 + Fulvestrant BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Recruiting USA | AUS 0
NCT06124118 Phase I Durvalumab Carboplatin + Paclitaxel Tumor Treating Fields for Locally Advanced NSCLC (NOVOCURE) Suspended USA 0
NCT06128551 Phase I RMC-6236 + RMC-6291 Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors Recruiting USA 0
NCT06130254 Phase I Adagrasib + Olaparib Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Recruiting USA 0
NCT06131398 Phase I AMG 355 + Pembrolizumab AMG 355 A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06131840 Phase I SGN-CEACAM5C A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Recruiting USA 0
NCT06140836 Phase III Repotrectinib Crizotinib A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 13
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0
NCT06162221 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Pembrolizumab + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Pembrolizumab + RMC-6291 Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC Recruiting USA 0
NCT06163391 Phase I SOT201 A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer Not yet recruiting USA | FRA | ESP | BEL 1
NCT06170788 Phase III Pembrolizumab + SKB264 Pembrolizumab MK-2870 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >= 50% (MK-2870-007) Recruiting USA | AUS 2
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06179160 Phase I Cetuximab + INCB161734 + Retifanlimab INCB161734 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Recruiting USA | AUS 0
NCT06188208 Phase I Pembrolizumab + VVD-130850 VVD-130850 A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors Recruiting USA 0
NCT06194448 Phase II Carboplatin + Pemetrexed Disodium Osimertinib Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Pemetrexed Disodium To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA) Not yet recruiting USA | ESP 8
NCT06208124 Phase Ib/II IMM-6-415 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors Recruiting USA 0
NCT06218914 Phase I NT-112 A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation Recruiting USA 0
NCT06219174 Phase Ib/II Eflornithine + Pembrolizumab Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) Recruiting USA 0
NCT06225427 Phase I Gilteritinib Gilteritinib for the Treatment of ALK NSCLC Not yet recruiting USA 0
NCT06225804 Phase I ABSK112 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer Recruiting USA 1
NCT06226766 Phase Ib/II JSKN033 JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors Not yet recruiting AUS 0
NCT06228482 Phase I 177Lu-DOTA-ABM-5G Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 Recruiting USA 0
NCT06237881 Phase Ib/II Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors Recruiting USA 0
NCT06238479 Phase I LY4101174 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06246110 Phase II Carboplatin + EIK1001 + Pembrolizumab + Pemetrexed Disodium Carboplatin + EIK1001 + Paclitaxel + Pembrolizumab A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer Recruiting USA 0
NCT06249282 Phase I Carfilzomib + Sotorasib Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer Not yet recruiting USA 0
NCT06253520 Phase I Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Recruiting USA 0
NCT06267001 Phase III Atezolizumab Atezolizumab + Tiragolumab A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15) Recruiting USA 2
NCT06268613 Phase I Pembrolizumab A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy Recruiting ESP 1
NCT06270082 Phase I IK-595 Study of IK-595 in RAS- or RAF-altered Advanced Tumors Recruiting USA 0
NCT06275360 Phase II Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL) Recruiting USA 0